Oral Presentations

Thursday, September 09, 2004

Antiinfectives - new and known non-synthetic compounds
Clinical studies and use of antibiotics
Pharmacokinetics and tissue penetration of antiinfectives
Antivirals - clinical studies
Resistance to antiinfectives
Mechanisms of pharmacological and biochemical action of antiinfectives
Antiinfectives - new and known synthetic compounds
Pharmacodynamics and experimental therapy of antiinfectives
Pharmacokinetics and tissue penetration of antiinfectives
Targeted delivery of antineoplastic agents
Antineoplastic agents - new and known synthetic compounds
Mechanism of tumor development and growth
Antineoplastic agents - new and known non-synthetic compounds
 Antineoplastic agents - clinical studies
Blood brain barrier
Adverse events, interactions and toxicity of antiinfectives
Clinical studies and use of antibiotics
Role of cells and their staining by dyes
Clinical studies and use of antibiotics
Antiinfectives - new and known synthetic compounds

Friday, September 10, 2004

Mechanisms of pharmacological and biochemical action of antiinfectives
Clinical studies and use of antibiotics
Pharmacokinetics and tissue penetration of antiinfectives
Antiinfectives - new and known synthetic compounds
Antineoplastic agents - new and known synthetic compounds
Antivirals & Antifungals - clinical studies
Pharmacodynamics and experimental therapy of antiinfectives
 Pharmacokinetics and tissue penetration of antiinfectives
Diagnostic tests in cancer / adverse events of cancer treatment & Adverse events of antineoplastic compounds
Antiinfectives - new and known non-synthetic compounds
Mechanism of tumor development and growth
In vitro action of antimalarials
Mechanisms of pharmacological importance
Targeted delivery of antineoplastic agents
Analytical techniques
Role of cells and their staining by dyes
Antineoplastic agents - new and known synthetic compounds
Targeted delivery of antineoplastic agents
 Antimalarial compounds - clinical studies
Adverse events, interactions and toxicity of antiinfectives
Antineoplastic agents - new and known non-synthetic compounds & Antineoplastic agents - clinical studies
Clinical studies and use of antibiotics
Clinical studies and use of antibiotics

Saturday, September 11, 2004

Microbiology & Resistance to antiinfectives
Antiviral agents
Mechanisms of pharmacological importance
Clinical studies and use of antibiotics
About mechanisms and Magic Bullets
Blood brain barrier
Mechanisms of action of antineoplastic agents including resistance
Agents involving the immune system
Design of drug delivery & Vaccination 

Oral Presentations

Thursday, September 09, 2004

Category:	Antiinfectives - new and known non-synthetic compounds

07:30 - 09:15 AM	Room assignment will be printed in the final program

353	Chemical Approaches for Improving ADME Properties of Lipoglycopeptide Antibiotics.
MU Y, LINSELL M, LEADBETTER M, FATHEREE P, NODWELL M, TRAPP S, LAM B, PACE J, SHAW JP, JUDICE K
Theravance Inc. South San Francisco, USA.

400	Therapeutic and Biotechnological Applications of Ribosomally Synthesized Antimicrobial Peptides.
PAPAGIANNI M
Department of Hygiene and Technology of Food of Animal Origin, School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

548	Antimicrobial Activity of Chitosan including practical application.
Seiichi Tokura, Tetsuaki Tsuchido, Kaoru Negoro* and Hiroshi Tamura
Faculty of Engineering and HRC, Kansai University, Suita, Osaka, Japan
*Negoro Sanngyo Co. Ltd. Kishiwada, Osaka, Japan.

593	Medicinal Plants of Southeast Asia: A Source for New Antibiotics?
Christophe Wiart
Department of Pharmacy, Faculty of Medicine, University of Malaya, Malaysia.

139	Why has there been so little success in finding new high activity antimicrobial compounds from plants?
ELOFF JN
Programme for Phytomedicine, University of Pretoria, South Africa.

119	CAY-1, a Plant-produced Saponin Active against Phytopathogenic and Medical Pathogenic Fungi. 
A. DE LUCCA1, S. BOUE1, J. BLAND1, L. WARTELLE1, C. SELITRENNIKOFF2, S. RENAULT2, M. CUSHION3, T. CLEVELAND1, and T. WALSH4.
1Southern Regional Research Center, USDA, New Orleans, LA USA; 2MycoLogics, Inc, Aurora, CO USA; 3Univ. of Cincinnati College of Medicine, Cincinnati, OH USA; 4 National Cancer Institute, National Institutes of Health, Bethesda, MD USA.  

562	Kola acuminata proanthocyanidins: a class of potent anti-trypanosomal drugs effective against the infective form of Trypanosoma brucei.
URADE Y1, Kubata BK1,2,*,Murakami N3, Merkel P4, Kabututu Z1,3 Martin SK2, Duszenko M4
1Osaka Bioscience Institute, Osaka, Japan; 
2US Army Medical Research Unit-Kenya, Nairobi, Kenya;
3Osaka University, Osaka, Japan; 
4Universität Tübingen, Tübingen, Germany.

Category:	Clinical studies and use of antibiotics

07:30 - 09:15 AM	Room assignment will be printed in the final program

230	Abnormal acquisition of intestinal flora in surgical neonates and the efficacy of synbiotic therapy for pediatric surgical patients with intestinal or respiratory failure.
KANAMORI Y1), HASHIZUME K1), SUGIYAMA M1), TOMONAGA T1), YUKI N2), TAKAHASHI T2), MOROTOMI M2).
1)Department of Pediatric Surgery, The University of Tokyo Hospital, Tokyo JAPAN
2)Yakult Central Institute for Microbiological Research, Tokyo JAPAN.

260	Outpatient Management of Low Risk Pediatric Oncology Patients with Fever and Neutropenia. How Do We Move from Clinical Trials to Clinical Practice?
KLAASSEN RJ
Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada.

483	The safety and efficacy of thalidomide in childhood tuberculous meningitis.
SCHOEMAN JF1, SPRINGER P1, JANSE VAN RENSBURG A1, SWANEVELDER S2, HANEKOM W3,  HASLETT P4, KAPLAN G5
1Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital; 2Biostatistics Unit, Medical Research Council; , Cape Town, South Africa 3Department of Pediatrics, University of Miami, Miami, Florida, 4Department of Microbiology and Immunology, University of Miami, Miami, Florida,and 5Public Health Research Institute, International Center for Public Health, Newark, NJ, USA.

035	Day-Care Based Management of Severe Pneumonia in Children with Injection Ceftriaxone.
ASHRAF H1, ALAM NH1, MAHMUD R2, JAHAN SA1, HAQUE F3, GYR K4 1ICDDR,B
Centre for Health and Population Research, Dhaka, Bangladesh; 2Radda MCH-FP Centre, Dhaka, Bangladesh, 3Institute of Child Health & Shishu Hospital, Dhaka, Bangladesh, 4University of Basel, Switzerland.

355	Updates on Antibiotic prophylaxis in Surgical Patients.
Nader D. Nader
FCCP

453	New Applications of Co-trimoxazole Therapy (Review).
ROZIN A, MILITIANU D, EDOUTE Y
Rambam Medical Center and B. Rappaport Faculty of Medicine, Israel-Technion Institute of Technology, Haifa, Israel.

267	IgY (Immunglobuline from egg-Yolk) - a tool to fight the emerging problem of antibiotic resistance.
KOLLBERG H1, LARSSON A2,CARLANDER D2.
1CF Center, University Children´s Hopital, Uppsala, Sweden, 2Dep. Med sciences, University Hospital, Uppsala, Sweden.

Category:	Pharmacokinetics and tissue penetration of antiinfectives

07:30 - 09:15 AM	Room assignment will be printed in the final program

521	Barriers to Magic Bullets; The Permeability of Mucosal Tissue to Therapeutic Agents.
SQUIER CA, KREMER M, WERTZ PW
Dows Institute for Dental Research, University of Iowa, Iowa City, Iowa, USA.

440	Tissue Penetration and Behaviour of Antibiotics in Acute Pancreatitis.
MAS MR, TASCI I, ISIK AT
Gulhane Medical Faculty, Ankara, Turkey.

508	Excretion and Resorption by the Skin.
SIMON GA
Israel Institute for Biological Research, Ness Ziona, Israel.

168	Cefotaxime and Ceftriaxone Cerebrospinal Fluid Levels During Treatment of Bacterial Meningitis in Children.
PN GOLDWATER
Microbiology & Infectious Diseases Department, The Women’s & Children’s Hospital, North Adelaide, South Australia, Australia.

078	Estimation of Amikacin Pharmacokinetic Parameters for South African Children.
BOTHA JH, FORSYTH NB
Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

253	Designing Antibiotics Dosage Regimens in Neonates Based on Population Pharmacokinetics(PPK): Comparative Study of Arbekacin (ABK), Vancomycin (VCM) and Panipenem (PAPM).
KIMURA T1, YAGO K1, SUNAKAWA K1
1Kitasato University Hospital, Kanagawa, Japan.

452	Antiinfective drug monitoring: time for change ?
ROUVEIX B.
Service de Pharmacologie Clinique, Hôpital Cochin–St Vincent de Paul, Paris, France.

Category:	Antivirals - clinical studies

08:00 - 09:00 AM	Room assignment will be printed in the final program

229	Adverse Effects on Brain Function caused by IFN-alpha -Evaluation from Quantitative-Electroencephalograms (q-EEG) in IFN- alpha Treated Hepatitis C Patients-
KAMEI S1, MATSUURA M2, TANAKA N3, ARAKAWA Y3, KOJIMA T2, MATSUKAWA Y 4, MIZUTANI T1, MORIYAMA M3, HIRAYANAGI K5
Divisions of 1Neurology, 3Gastroenterology and Hepatology, and 4Hematology and Rheumatology, Department of Medicine, and Departments of 2Neuropsychiatry, and 5Hygiene and Public Health, Nihon University School of Medicine, Tokyo, Japan.

471	Selective Myeloid Cell Purging as a Novel Adjunct to Interferon-a+Ribavirin Combination Therapy in Patients with High Plasma HCV Viraemia Resistant to Interferon: An Enhanced Immune Function Against HVC.
Saniabadi AR1, Sawada K2, Hirata I1, Fukunaga K.3
1Japan Immunoresearch Laboratories; 2Fujimoto Hospital Medicine; 3Hyogo College of Medicine, Japan.

054	Treatment of HIV-1/AIDS Patients with CpG ODN May Stop the Pandemic.
BECKER Y
The Hebrew University of Jerusalem, Jerusalem, Israel.

378	Toxoplasmosis In HIV/AIDS Patients: A Current Situation.
NISSAPATORN VEERANOOT1, LEE CHRISTOPHER2, QUEK KIA FATT3, LEONG CHEE LOON2, MAHMUD ROHELA1, ABDULLAH KHAIRUL ANUAR1
1Department of Parasitology, 3Department of Social and Preventive Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia. 2Department of Medicine, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.

Category :	Resistance to antiinfectives

08:15 - 10:15 AM	Room assignment will be printed in the final program

584	In vitro Antimicrobial Resistance in Bacteria Exposed to Residue Level Exposures of Antimicrobial Drugs, Pesticides and Veterinary Drugs.
D KLEINER, SE KATZ, PL WARD
Cook College, NJAES, Rutgers, the State University of New Jersey, New Brunswick, NJ, USA.

144	Strategies for Containment of Antibiotic Resistance in Developing Countries – Lessons from South Africa.
ESSACK, SY
University of KwaZulu-Natal, Durban, South Africa.

095	Yearwise (1989-2003) prevalence of drug resistance to various drugs among gram negative bacilli isolated from hospitalized cases in Central India.
Chitnis S, Chitnis V, Hemwani N and Chitnis DS.

162	Isolation of Multidrug-Resistant Stenotrophomonas maltophilia from a Marine Cultured Fish.
FURUSHITA M1, 2, MAEDA T1, OKAMOTO A2, OHTA M2, SHIBA T1
1Department of Food Science and Technology, National Fisheries University, Shimonoseki, Japan; 2Graduate School of Medicine, Nagoya University, Nagoya, Japan.

237	Antibiogram of Bacteria from Slaughter Animals on the Data of Resistance Monitoring System in 2003.
J-KASZANYITZKY É, JÁNOSI, S
Central Veterinary Institute, Budapest, Hungary.

122	Antiparasitic Drug Resistance: Lessons from Ivermectin and a Model Nematode.
DENT JA1
1McGill University, Montreal, QC, Canada.

281	Evolution Of Drug Resistance In A University Hospital In Singapore (NUH).
KUMARASINGHE G, JAYASURYA A, LIM SM, CHOW C.
National University Hospital, Singapore.

338	Antimicrobial Usage Data in Humans and Food Animals from 1995 to 2001in Kenya.
MITEMA, ES1, KIKUVI, G1
1Pharmacology and Toxicology Laboratory, Faculty of Veterinary Medicine, University of Nairobi, Nairobi, Kenya.

Category:	Mechanisms of pharmacological and biochemical action of antiinfectives

09:30 - 11:45 AM	Room assignment will be printed in the final program

563	Anti-Inflammatory Activity of Macrolides and Fluoroquinolones on Human Endothelial Cells.
URIARTE SM1, MOLESTINA RE1, MILLER RD1, RAMIREZ JA1, SUMMERSGILL JT1.
1University of Louisville School of Medicine, Louisville, KY, USA.

358	Crystal Structure Based Assembly of the MexAB-OprM Multidrug Efflux Pump in Pseudomonas aeruginosa.
NAKAE, T1, AKAMA, H1, MATSUURA, T2, TSUKIHARA, T2, and NAKAGAWA, A2
1Tokai University School of Medicine, Isehra, Japan; 2Osaka University Institute for Protein Research, Suita, Japan.

084	Polymyxin B-Mediated Selective Lipid Exchange: Implications in Antibacterial Action.
CAJAL Y1
1Universitat de Barcelona, Barcelona, Spain.

324	Monosaccharide Lipid A Analogues; Their Potencial as Magic Bullets to Enhance Host Innate Immunity against Microbial Infections.
MATSUURA M
Department of Infection and Immunity, Jichi Medical School, Tochigi, Japan.

333	The effect of combined antimicrobial treatment on prokaryotic cells and on certain groups of eukaryotic cells.
MILANKOVITS M.
Hungarian National Institute of Genitourinary Medicine Foundation, Budapest,Hungary.

406	Mechanisms of Induction and Regulation of Gut Mucosal Immune Stimulation by Non-Pathogenic Bacteria.
Maldonado Galdeano C.1,2, Dogi C.1, Bibas Bonet M.E.1,2, Chaves S1. And Perdigón G.1,2
1CERELA, Chacabuco,Tucumán, Argentina.
2Cátedra de Inmunología, FBQyF, Universidad Nacional de Tucumán, Argentina.

409	The Interface of Triosephosphate Isomerase of Trypanosoma cruzi as a Target for the Development of New Drugs for Chagas’ Disease.
PEREZ-MONTFORT R1, GOMEZ-PUYOU A1
1Instituto de Fisiologia Celular, Universidad Nacional Autonoma de Mexico, Mexico DF, Mexico.

514	Forcing Nanoscopic Infectious Agents to Incorporate Antiinfectives by Exposure to Moderate Laser Light Intensities – Solutions Inspired by Nature.
SOMMER, AP
Central Institute of Biomedical Engineering, University of Ulm, Ulm, Germany.

542	A New Type of Magic Bullet? Therapeutic Agents that Modify Rather than Kill the Pathogen.
TAYLOR PW1, MUSHTAQ N1, LUZIO JP2
1School of Pharmacy, London, United Kingdom; 2Cambridge Institute for Medical Research, Cambridge, United Kingdom.

Category:	Antiinfectives - new and known synthetic compounds

09:30 - 11:30 AM	Room assignment will be printed in the final program

394	Structural Modification of Dibenzosuberanylpiperazine and Diphenylacethyl- piperazine Derivatives Mainly for Efficient Reduction of Chloroquine Resistance in Plasmodium chabaudi.
OSA Y1, KOBAYASHI S2, SATO Y1, SUZUKI Y2, TAKINO K1, HIKIMA Y1, TAKEUCHI T2, MIYATA Y3, SAKAGUCHI M3, TAKAYANAGI H1, NAGASE H1
1Kitasato University, Tokyo, Japan, 2 Keio University, Tokyo, Japan, 3 Pola Chemical Industries, Inc., Yokohama, Japan.

067	New pyrrole derivatives of BM 212: a new class of antimycobacterial agents.
Biava M1*, Porretta1 GC, Pompei R2, Laconi S2, Manetti F3, Botta M3
1Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive, Università "La Sapienza", Rome
2Cattedra di Microbiologia Applicata, Facoltà di Scienze Matematiche Fisiche Naturali, Università degli Studi di Cagliari, Cagliari, Italy; 3Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Aldo Moro snc.

200	Development of Hexadecyloxypropyl-cidofovir: An Oral Drug for the Prevention and Treatment of Smallpox.
HOSTETLER, KY
Department of Medicine, University of California, San Diego and the San Diego VA Healthcare System, San Diego, California, USA.

505	Improving and Assessing the Effectiveness of Antiinfective Drugs by Molecular Design and Theranostic Devices.
SIA SK
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA (USA).

071	Evidence for in vitro trypanocidal activity of methylene blue, but in vivo failure.
Caroline Boda, Bertin Enanga, Bertrand Courtioux, Christian Breton, Bernard Bouteille
UPRES-EA 3174 Neuroparasitologie et neuroépidémiologie tropicale
Faculty of medicine, Limoges Cedex (France).

303	Antileishmanial Drug Discovery & Development: Experiences With Drug Candidate PX-6518.
MAES L1, COS P1, VANDEN BERGHE D1, VAN PUYVELDE L2
1Laboratory for Microbiology, Parasitology & Hygiene, University Antwerp, Belgium; 2Vietnamese Academy of Science and Technology, Hanoi, Vietnam.

092	New "Magic Bullets" and Hypermutability Leading to Cytotoxic Resistance Emergence in Escherichia coli.
CHEREPENKO YI1, POTYAHAYLO AL1, HOVORUN DM1
1Institute of Molecular Biology and Genetics, Kyiv, Ukraine.

500	Prolonging the action of protein and peptide drugs by a novel approach of reversible PEGylation.
Haim Tsubery1,2, Marina Mironchik1, Mati Fridkin2 and Yoram Shechter1
Departments of 1Biological Chemistry and 2Organic Chemistry
The Weizmann Institute of Science, Rehovot, Israel.

Category:	Pharmacodynamics and experimental therapy of antiinfectives

10:00 - 11:45 AM	Room assignment will be printed in the final program

382	Monte Carlo Simulation versus S.pneumoniae of Levofloxacin 500mg, 750mg and 1000mg Once Daily Compared to Gatifloxacin 200mg and 400mg Once Daily Administered to Hospitalized Patients with Community Acquired Pneumonia (CAP):  Dose and Age Stratification Study.
NOREDDIN AM1,2, MARRAS TK4,  CHAN CK4, HOBAN DJ2,3 and Zhanel GG 2,3
1College of Pharmacy, University of Minnesota, Duluth, MN, USA; 2Faculty of Medicine, University of Manitoba; 3Health Sciences Centre, Winnipeg, MB; 4University of Toronto, Toronto, ON, Canada.

232	The impact of dosing frequency on patient compliance with antiinfectives – is there an evidence that once-daily dosage is a real solution?
KARDAS P1
1Medical University of Lodz, Lodz, Poland.

632	Mutant Selection Window.
DRLICA K, ZHAO X, LI X, WANG J, URBAN C, PERLIN D
Public Health Research Institute, Newark, NJ, USA

635	APC Anti-infective Action Is Augmented By APC Activation Of Protein C.
HASSOUNA HI, Penner J
Department of Medicine Michigan State Universitym, Clinical Center East Lansing, MI, USA

451	Subcellular Drug Transport and the Effectiveness of Anti-infectives.
CHEN V1, SHEDDEN K1, ELLIOTT A1 AND ROSANIA GR1
1University of Michigan, Ann Arbor.

388	Invasive group A Streptococcus infections followed by intranasal superinfection with influenza A virus in mice: Cure and prevention of lethal synergism.
OKAMOTO S1,3, HAMADA S1, KAWABATA S1,2
1Osaka University Graduate School of Dentistry, Suita-Osaka, Japan; 2Japan Science and Technology Agency, Kawaguchi-Saitama, Japan; 3Fukuoka Dental College, Fukuoka, Japan.

202 	Treatment of Toxocara canis (Nematoda) Infection in Mice with Albendazole Incorporated into Liposome Carriers and  Immunomodulator -glucan.
HRČKOVA G, VELEBNY S, TOMAŠOVIČOVA O, ČORBA J 
Parasitological Intitute, Košice, Slovak Republic.

Category:	Pharmacokinetics and tissue penetration of antiinfectives

10:30 - 11:45 AM	Room assignment will be printed in the final program

105	Prediction of in vivo Human Pharmacokinetics from Nonclinical Data.
COOK CC
Baxter Healthcare, Round Lake IL, U.S.A.

408	EFFECT OF PARASITISM ON THE PLASMA DISPOSITION AND BIOAVAILABILITY OF DORAMECTIN IN LAMBS.
R. Pérez¹, C.  Palma¹, I. Cabezas¹,  L. Rubilar¹    and M. Arboix2. 
1: Facultad Medicina Veterinaria, Universidad de Concepción. 
Chillán - Chile. 2. Laboratorio Farmacología. Facultad Veterinaria. Universidad  Autonoma de Barcelona, Bellaterra, Barcelona – España.

481	The Relative Bioavailability of Three Newly Developed Albendazole Formulations: a Randomized Cross-Over Study in Healthy Volunteers.
IM RIGTER1, HG SCHIPPER1, RP KOOPMANS1, HJM VAN KAN1, HG FRIJLINK2, PA KAGER1, HJ GUCHELAAR1
Academic Medical Center1, University of Amsterdam, The Netherlands. University of Groningen2, The Netherlands.

023	Antibiotic dosing in hepatic failure.
AMARAPURKAR DN
Department of Gastroenterology & Hepatology Bombay Hospital & Medical Research Centre, Mumbai India.

129	A New Method to Predict Glomerular Filtration Rate and Adjust Drug Dose to Renal Function.
DONADIO C, CONSANI C, ARDINI M, BERNABINI G, CAPRIO F, GRASSI G, 
LUCCHESI A 
Deparment.of Internal Medicine – Nephrology, University of Pisa, Pisa, Italy.

Category:	Targeted delivery of antineoplastic agents

11:45 AM - 02:00 PM	Room assignment will be printed in the final program

294	Radiolanthanides for Pretarget and Conventional Radioimmunotherapy of Cancer:  “Magic Bullets” versus “Smart Bombs”.
LEWIS MR1,2,3, MOHSIN H4, SIVAGURU G1, JIA F1, BRYAN JN1, SHELTON TD5, HOFFMAN TJ5, CUTLER CS6, KETRING AR6, ATHEY PS7, SIMÓN J7, FRANK RK7, AXWORTHY DB8, JURISSON SS4,6
1Veterinary Medicine and Surgery, 2Radiology, 3Nuclear Science and Engineering Institute, 4Chemistry, 5Internal Medicine, 6Research Reactor Center, University of Missouri, Columbia, MO; 7The DOW Chemical Company, Freeport, TX; 8Aletheon Pharmaceuticals, Seattle, WA, USA.

439	Tumor-targeting of Antineoplastics using Nano-sized Drug Carriers and Focused Ultrasound.
Rapoport NY
University of Utah, Salt Lake City, Utah, USA.

014	Targeted Block Copolymer Drug Formulations for Oncology. Pre-Clinical and Clinical Experience.
Alakhov V
Supratek Pharma Inc., Dorval, Quebec, Canada.

292	avß3-Integrin Targeted Camptothecin Conjugates.
LERCHEN HG1, BAUMGARTEN J1, LYNCH M2, ALBERS M1, BRUEGGEMEIER U1, BURGER AM3, FIEBIG HH3.
1Bayer HealthCare AG, Wuppertal, Germany; 2Bayer Corp. West Haven, USA, 3Oncotest GmbH, Freiburg, Germany.

301	Polymer therapeutics and cancer targeting principle, EPR-effect, ---- towards the magic bullets.
MAEDA H
Sojo University; Kumamoto University, and BioDynamics Research Laboratory, Kumamoto, Japan.

336	Extracellular and Intracellular Molecular Targeting of Drug Delivery System to Cancer Cells.
MINKO T
Rutgers, The State University of New Jersey, Piscataway, NJ, USA.

370	“Targeted” Molecular Chemotherapy for Brain Tumors – Searching for the “Magic Bullet”.
NEWTON HB
Division of Neuro-Oncology and Dardinger Neuro-Oncology Center, Ohio State University Medical Center and James Cancer Hospital & Solove Research Institute, Columbus, Ohio, USA.

098	Antisense DNAs: Targeted Genetic Medicine to Treat Cancer.
CHO-CHUNG YS
Cellular Biochemistry Section, Basic Research Laboratory, National Cancer Institute, NIH, Bethesda, MD, U.S.A.

051	Novel Oligonucleotides Inhibiting STAT3: Use in Hormone-Refractory Prostate Cancer.
BARTON BE, MURPHY TF, SHU P, HUANG HF, BARTON A
UMDNJ-New Jersey Medical School, Newark, NJ, USA.

Category:	Antineoplastic agents - new and known synthetic compounds

12:00 - 01:30 PM	Room assignment will be printed in the final program

104	Metal Based Anti-Cancer Drugs with Anti-Leukemic Thiobases and COX-inhibitors as Ligands.
CINI R
Department of Chemical and Biosystem Sciences and Technologies, University of Siena, Siena, Italy.

344	An Innovative Approach for DNA Inactivation Using Combination of Phenothiazine Dyes, Rhodium Complex, and Visible Light.
Taj Mohammad
Purdue University, Department of Chemistry, and Department of Forestry and Natural Resources, IN, U. S. A.

519	Antineoplastic polyanions in cancer strategy.
SORIMACHI K
Dokkyo University School of Medicine, Mibu, Japan.

100	Enhanced Antineoplastic Efficacy in vivo of Lactone-Stabilized Camptothecins by Chemical Modification or Liposomal Delivery.
CHOW DSL1, LI X1, GONG L1, WOLFE MD1, GIOVANELLA BC2
1College of Pharmacy, University of Houston, Houston, TX, USA; 2Stehlin Foundation for Cancer Research, Houston, TX, USA.

477	Destruction of Human Breast Cancer Cells by Tumor-targeted Salmonella typhimurium.
	SCHATTEN H1, FEA, A1 and EISENSTARK, A1
1Dept. of Veterinary Pathobiology, Univ. of Missouri-Columbia, Columbia, MO, USA, 2Cancer Research Center, Columbia, MO, USA.

504	Development of Tumor-Activated Prodrugs of Cytotoxics (TAC).
SHIMMA N1, ISHITSUKA H2, OKABE H1, UMEDA I1, Hattori K1, Miwa M1
1Chugai Pharm. Co. Ltd., Kamakura, Japan; 2Roche Diagnostics, Tokyo, Japan.

Category:	Mechanism of tumor development and growth

12:00 - 13:30 PM	Room assignment will be printed in the final program

397	A Mathematical Model for Capillary Formation and Development in Tumor Angiogenesis.
PAMUK S
University of Kocaeli, Kocaeli, Turkey.

319	Intracellular Targeting of 10B compounds  (10BSH) to Solid Tumors by Transferrin-Pegylated Liposomes (TF-PEG-LP), for Boron Neutron-Capture Therapy (BNCT).
Maruyama K1, Kasaoka S1, Takizawa T1, Suzuki R1, Utoguchi N1, Yanagie H2, 
Shinohara A3, Ono K4
1Teikyo University, Kanagawa, Japan; 2University of Tokyo, Tokyo, Japan; 3Juntendo University, Tokyo, Japan; 4Kyoto University, Kyoto, Japan.

598	Mechanisms of Acute 5-Fluorouracil Chemotherapy-Induced Bone Growth Arrest in Young Rats.
CJ Xian, J Cool, BK Foster
Department of Orthopaedic Surgery, Women’s and Children’s Hospital, South Australia.

289	Detection of PDGFRB and ETV6 gene rearrangement in five cases of atypical chronic myeloid leukemia with 5q chromosome abnormalities.
LAZARIDOU A, MAVROUDI S, CHRISTAKIS JI
Cancer Hospital of Thessaloniki, Hematology Department, Greece.

480	Increasing tissue and cell penetration of therapeutic DNA by electrotransfer.
SCHERMAN D., BIGEY P, BLOQUEL C, TROLLET C
Laboratoire de Pharmacologie Chimique et Génétique, Faculté de Pharmacie Paris 5.

568	Inhibition of the RhoC GTPase-Mediated Inflammatory Breast Cancer Phenotype by Farnesyl Transferase Inhibitors.
GROH KE, RADUNSKY GS and VAN GOLEN KL
The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

Category:	Antineoplastic agents - new and known non-synthetic compounds

12:45 - 03:15 PM	Room assignment will be printed in the final program

485	Selenium in Cancer Prevention and Therapy.
G.N.Schrauzer
University of California, San Diego, USA.

218 	Characterization of Vitamin C: K3 Induced Autoschizis in Human Bladder Cancer Cell Lines.
Jamison JM1, Summers JL1, Gilloteaux J2, Buc-Calderon P3, Taper HS3 
1Summa Health System/ NEOUCOM, Akron, Ohio, USA; 2American University of the Caribbean, St. Maarten, Netherland Antilles, West Indies; 3Université Catholique de Louvain,  Brussels-Woluwé, Belgium.

201	Molecular Mechanism of Apoptosis Induction by Polyphenolic Compounds: Targeting Reactive Oxygen Species (ROS) and Mitochondria.
HOU D-X, Kubo M, Harazono K, Imamura I, Morishita A, Tong X, Uto T, Takeshita T, Fujii M.
Faculty of Agriculture, Kagoshima University, Kagoshima, Japan.

547	VEGF and its intrinsic inhibitory protein in human cancer.
TOI M1, BANDO H1, WEICH HA2
1 Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome, Tokyo, Japan
2 German Research Center for Biotechnology, Braunschweig, Germany.

027	Conjunction of Small Interfering RNAs and Tumor-Penetrating Peptides Could Provide Novel Antineoplastic Agents.
Aoki Y1,2, Oguchi S1, Kumagai M1, Suzawa K1, Otsuki T2, Miyamoto T2, Hashizume K2, Nakajima K3
1Department of Internal Medicine, Matsumoto National Hospital, Matsumoto, Japan; 2Department of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University Graduate School, Matsumoto, Japan; 3Peptide Institute, Inc., Osaka, Japan.

385	Screening of Natural Compounds for Inhibitory Activity on Tumor Cell Migration and Metastasis.
OGASAWARA M, MATSUBARA T, MATSUNAGA T, TAKAHASHI S, SUZUKI H
Toyama Prefectural Institute for Pharmaceutical Research, Toyama, Japan.

024	Leptosins Isolated from Marine Microorganism Leptoshaeria sp. Inhibit DNA Topoisomerases and Induce Apoptosis in a Panel of Human Cancer Cell Lines.
Andoh T1, Yanagihara M1, Takahashi-Sasaki, N1, Yamamoto S1. Numata A2, Yamori T3
1Soka Univ,ersity Tokyo, 2Osaka University of Pharmaceutical Sciences, Osaka, 3Foundation for Cancer Research, Tokyo, Japan.

387	A Newly Identified Antineoplastic Molecule Derived from Streptococcus pyogenes: Involvement of Toll-Like Receptor (TLR) 4 Signaling.
Okamoto M
Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Tokushima, Japan.

223	An antineoplastic compound from Murdannia loriformis.
JIRATCHARIYAKUL W1, VONGSAKUL M2, SUNTHORNSUK L1, MOONGKARNDI P1, SOMANABANDHU A1, OKABE H3, FRAHM AW4 
1Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; 2Faculty of Science, Mahidol University, Bangkok, Thailand; 3Laboratory of Pharmacognosy and Plant Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; 4Dept. of Pharmaceutical Chemistry, Albert-Ludwigs-University, Freiburg, Germany.

093	Flying Bullets: Cytokine-like Antineoplastic Peptides from Insects.
CHERNYSH SI1, PLESKACH VA2, TULIN DV1
1St.Petersburg University, St.Petersburg, Russia; 2Institute of Cytology, St.Petersburg, Russia.

Category: 	Antineoplastic agents - clinical studies

02:00 - 04:35 PM	Room assignment will be printed in the final program

	Individual dose adaptation in cancer chemotherapy
Jaehde U.
Inst. of Pharmacy, Dept. Clinical Pharmacy, University of Bonn, Germany.

160	Tissue Concentrations of some Antineoplastic Drugs in Cancer Patients.
FURLANUT M1 , FRANCESCHI L1, GIORDA G2, DE MANZONI G3, PASINI F3; CARTEI G4, CAGOL PP5
1DPMSC University of Udine, Italy; 2CRO Aviano, Italy; 3General Surgery, University of Verona, Italy; 4Oncology Unit, General Hospital, Padua, Italy;5General Surgery, University of Udine, Italy.

191	Magic Bullets Against Non-Small Cell Lung Cancer (NSCLC) are Becoming A Reality – Targets are in Sight.
HIRSH V 1
1 Royal Victoria Hospital, McGill University, Montreal, Canada.

350	Clinical Features, Response to Treatment, and Survival in Small Cell Lung Cancer: Effect of Histological Variability.
Moran EM1,2, Iyer PR1,2, Kaneshiro CA2
1Department of Medicine, University of California, Irvine, Irvine, California; 2Long Beach VA Healthcare System, Long Beach, California, USA.

428	Antiangiogenic drugs for chemotherapy of bladder tumors.
Possati L1, Margiotta C1, Rocchetti R1, Calza R1, Talevi S1, Corallini A2
1Institute of Microbiology and Biomedical Sciences, Polytechnic University of Marche, Ancona, Italy; 2Department of Experimental and Diagnostic Medicine, Section of Microbiology, University of Ferrara, Italy.

450	Urinary Bladder Carcinogenesis after the Chernobyl Accident in Ukraine (Molecular Mechanisms).
ROMANENKO AM1, VOZIANOV AF1, FUKUSHIMA S2
1Institute of Urology, Kiev, Ukraine; 2First Department of Pathology, Osaka City University Medical School, Osaka, Japan.

426	Sequential Chemotherapy in Advanced Colorectal Cancer: Results of Five Arms Study.
POPOV I1, JELIC S1, KRIVOKAPIC Z2, MICEV M2, JEZDIC S1, ZDRAVKO Z1, KEZIC I1.
1Institut of Oncology and Radiology, Belgrade, Serbia; 2First University Surgery Clinic, Belgrade, Serbia.

606	A Novel Chemotherapeutic Strategy against Colorectal Cancer Manipulating Dual Cell Death by Five-fluorouracil (5-FU); High-Dose Shorter plus Low-Dose Metronomic Regimen.
Yoshikawa R 1,2, Yanagi H 1, Noda M 1, Hashimoto-Tamaoki T 2, 3, Kusunoki M 4, and 
Yamamura T 1, 2.
12nd Dept of Surg, 2Inst for Adv Med Sci, 3Dept of Genet, Hyogo College of Medicine, Nishinomiya, Hyogo; 42nd Dept of Surg, Mie Univ, Tsu, Mie, JAPAN.

215 	High-Dose Methotrexate With Leukovorin Rescue:  Impact On The Management of Osteosarcoma.
JAFFE N1
1University of Texas M. D. Anderson Cancer Center, Division of Pediatrics, Houston, TX.

615	Latest Developments in Drug Treatment for Skin Cancers.
ZEITOUNI NC
Roswell Park Cancer Institute, Buffalo, New York, USA.

Category:	Blood brain barrier

02:00 - 03:15 PM	Room assignment will be printed in the final program

459	Amylin, the Regulation of Energy Homeostasis, and the Blood-Brain Barrier.
RUSHING PA
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.

543	Brain-to-Blood Efflux Transporters for Hydrophilic Endogenous Substrates at the Blood-Brain Barrier as a CNS detoxifying system.
TERASAKI T1, OHTSUKI S2
1New Industry Creation Hatchery Center (NICHe), and 2Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan; 3CREST and SORST, Japan Scinece and Technology Agency, Japan.

128	Passage of Vasoactive Intestinal Peptide (VIP) Across the Blood-Brain Barrier and Comparison with Respect to the Passage of VIP/PACAP/Secretin Family Members.
DOGRUKOL-AK D1, BANKS WA2, TUNCEL N3, TORE F4, TUNCEL M1
1Department of Analytical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey, 2GRECC, Department of Internal Medicine, Division of Geriatrics, School of Medicine, Veterans Affairs Medical Center and Saint Louis University, St. Louis, MO, USA, 3Department of Physiology, Faculty of Medicine, Osmangazi University, 26480 Eskisehir, Turkey, 4Department of Physiology, Izzet Baysal Medical Faculty, Abant Izzet Baysal Universty, 14280 Bolu, Turkey.

468	Evidence of Pralidoxime Iodide (2-PAM) Penetration Across the Blood-Brain Barrier.
Sakurada K1, Matsubara K2, Ohta H1, Ohmori T1, Takatori T1
1National Research Institute of Police Science, Chiba, Japan; 2Asahikawa Medical College, Asahikawa, Japan.

251	Accumulation of Mini-plasmin in the Cerebral Capillaries Causes Destruction of the Blood-brain Barrier (BBB) in Influenza-associated Encephalopathy (IAE) in Mice: Proposal for a Therapeutic Target Molecule of Brain Edema of IAE.
KIDO H, YAMADA H, OKUMURA Y, YAO DF, CHEN Y, YANO M
Institute for Enzyme Research, The University of Tokushima, Tokushima, Japan.

Category:	Adverse events, interactions and toxicity of antiinfectives

02:00 - 03:15 PM	Room assignment will be printed in the final program

365	A Mathematical Model for the Efficacy and Toxicity of Aminoglycosides.
C. NEEF 1, A .H. Koop 2,  S.A. van Gils2
1Medisch Spectrum Twente,Enschede, The Netherlands; 2  University of Twente, Enschede, The Netherlands.

551	Effect of Rapamycin on Hepatocyte Function and Proliferation Induced by Growth Factors.
TOMIYA T1, INOUE Y1, YANASE M1, ARAI M1, IKEDA H1, TEJIMA K1, NAGASHIMA K1, NISHIKAWA T1, WATANABE N1, OMATA M1, FUJIWARA K2
1Department of Gastroenterology, University of Tokyo, Tokyo, Japan, 2Third Department of Internal Medicine, Saitama Medical School, Saitama, Japan.

286	Fatal Adverse Drug Reactions (ADR): A Forensic Perspective on the Use of Anti-microbial and Anti-neoplastic Agents.
Lau G
Centre for Forensic Medicine, Health Sciences Authority, Singapore.

555	Cytochrome P450 Enzyme Activity Depression in Critically ill Patients: Cause of Drug Interactions involving Antimicrobial Agents.
PATIPARN TOOMTONG1
1Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

048	HAART-ASSOCIATED METABOLIC SYNDROME AND CARDIOVASCULAR RISK.
Giuseppe Barbaro,MD, Giorgio Barbarini1
Department of Medical Pathophysiology, University of Rome “La Sapienza”, Italy. 1Department of Infectious and Tropical Disease, Policlinico S.Matteo, University of Pavia, Italy.

Category:	Clinical studies and use of antibiotics

02:15 - 03:30 PM	Room assignment will be printed in the final program

430	Consumer knowledge and demand for antibiotics; a Sri Lankan experience.
Premaratna R., Weerasinghe M., Vipulanayake T., Perera C., Balasooriya H. de Silva H.J.
Department of Medicine, Faculty of Medicine, University of Kelaniya, Sri Lanka.

525	State of the Art:  Lyme Disease and the Legacy of Paul Ehrlich.
STRICKER RB1, LAUTIN A2, BURRASCANO JJ3
1California Pacific Medical Center, San Francisco, CA, USA; 2New York University School of Medicine, New York, NY, USA and 3East End Medical Associates, East Hampton, NY, USA.

179	A Multispecies Biofilm Model Allows Prediction of Clinically Effective Concentrations of Antimicrobials in Oral Care Products.
B. Guggenheim1, T. Boyd2 and A. Gaffar2
1University of Zurich, Institute for Oral Biology, Switzerland, 2Colgate Palmolive Company, Piscataway, NJ, USA.

356	Role of Antiinfectives in the Treatment of Periodontitis.
NAGASAWA T1, KOSHY G1, ISHIKAWA I1
1Periodontology, Department of Hard Tissue Engineering, Graduate School, Tokyo Medical and Dental University.

097	Antibiotics in the Management of Acute Pharyngitis/Tonsillitis - Survey of  Family Physicians in Northeastern Poland.
Chlabicz S, Oltarzewska AM, Pytel-Krolczuk B
Medical University Bilystok, Bialystok, Poland.

Category:	Role of cells and their staining by dyes

03:30 - 05:15 PM	Room assignment will be printed in the final program

359	Staining Bacterial Cells: From Ehrlich to the Present.
NANNINGA N
Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.

109	CELL STAINING WITH TRADITIONAL TURKISH MADDER ROOT.
CÜCER N1, GÜLER N2, ÝMAMQGLU N1, DEMIRTAS H1
1Erciyes University, Medical Faculty, Medical Biology Department. Kayseri-TURKEY
2Erciyes University, Veterinary Faculty, Pharmacology Department, Kayseri-TURKEY.

159	Application of Quantitative Structure-Activity Relationships (QSAR) to Dye Affinity for Natural Fibre: a Challenge for the Domain.
FUNAR-TIMOFEI S 1, KURUNCZI L 2, SIMON Z 1
1'Coriolan Dragulescu' Institute of Chemistry, Timisoara, Romania; 2’Victor Babes’ University of Medicine and Pharmacy, Timisoara, Romania.

015	Fluorescence dyes, a powerfull tool for structural characterization of macromolecules and cells.
ALBANI JR
Laboratoire de Biophysique Moléculaire, Université des Sciences et Technologies de Lille, Villeneuve d’Ascq Cédex, France.

322	Intermolecular Interactions of Functional Dyes in the Solid State  – Color Polymorphism in Fluorescent Pyazine Dyes –
MATSUMOTO S1, UCHIDA Y1, YANAGITA M2
1Yokohama National University, Yokohama, Japan; 2Nippon Soda Co., Ltd., Chiba, Japan.

636	Bifunctional effect of 17-estradiol on macrophage.
HONG MIN, ZHU QUAN
National Standard Lab of Pharmacology for Chinese Materia Medica, Nanjing, China.

580	The Use of Dyes in the Study of Microencapsulated Pheromone for Control of Oriental Fruit Moth.
Waldstein DW1, Gut L2
1Missouri State Fruit Experiment Station, SW Missouri State University, Missouri, USA
2Michigan State University, Michigan USA.

Category:	Clinical studies and use of antibiotics

03:45 - 05:30 PM	Room assignment will be printed in the final program

236	Antibiotic treatment of respiratory infections in cystic fibrosis (CF) – the Stockholm policy and perspective.
KARPATI F, Hjelte L
Stockholm CF Centre, Children’s Hospital, Karolinska University Hospital, Huddinge, Sweden.

364	Hepatocyte growth factor is a rapid therapeutic indicator within the first day of treatment in pneumonia.
NAYERI F1, ABEDNAZARI H, MILLINGER E1, BRUDIN L2
University Hospital, Linköping1 and County Hospital, Kalmar2, Sweden.

185	Role of different risk factors in the development of Bronchial   asthma in Bangladesh: an age, sex and economic STATUS MATCHED PROSPECTIVE STUDY.
M Rashidul Hassan1, AKM Fazlur Rahman2 ARM Luthful Kabir2, M Ali Hossain1, Asif M Mahmud1, M Ruhul Amin3, Kazi S Bennoor1, M Mostafizur Rahman1 et al
1.NIDCH, Dhaka. 2. ICMH, Dhaka. 3. BICH, Dhaka: Bangladesh.

060	Ehrlich's Theory Of Drug Action And Anti-tuberculous Gold Therapy.
TG BENEDEK
University of Pittsburgh, Pittsburgh, PA.

304	Antibiotics in nosocomial infection and Culture sensitivity - An experience over 25 years.
A.K.Mahapatra
Dept.of Neurosurgery, AIIMS, New Delhi-110029, India.

231	Impact of Extended Spectrum b-Lactamase  Producers in the Management of  Nosocomial Infections.
REBA KANUNGO*, ANANTHKRISHNAN, SHANMUGANATHAN, SANJAYBHATTACHARYA, S.KUMAR,RENU MATHEW*, SHASHIKALA*, &SRINIVASAN*
Department of Clinical Microbiology, Pondicherry Institute of Medical Sciences*, JawharlalInstitute of Medical Education and Research Pondicherry India.

411	Beta-Lactam/Beta-Lactamase Inhibitor (BLBI) Antibiotics are a Rational Choice for Treatment of Serious Infection with Extended-Spectrum Beta-Lactamase (ESBL) producing Bacteria.
PETERSON, LR
Evanston Northwestern Healthcare Research Institute and Northwestern University, Evanston, IL, USA.

Category:	Antiinfectives - new and known synthetic compounds

03:45 - 05:30 PM	Room assignment will be printed in the final program

085	Anti-Microbial Efficacy of Hydroxyapatite-Chlorhexidine Coated External Fixation Pins.
CAMPBELL, AA1, LI, XS1, NELSON, BJ2*, BOTTONI, C3, DEJONG, ES4*, BROOKS, DE4
1 Pacific Northwest National Laboratory, Richland WA 
2Dwight D. Eisenhower Army Medical Center, Ft Gordon, GA 
3Keller Army Community Hospital, West Point, NY 
4U.S. Army Institute of Surgical Research, Fort Sam Houston TX.

106	Antimicrobial Drug Discovery: Need For A More Integrated Approach !
COS P1, VANDEN BERGHE D1, PIETERS L2, MAES L1
1Laboratory for Microbiology, Parasitology and Hygiene, 2Laboratory for Pharmacognosy and Phytochemistry, University of Antwerp, Belgium.

121	Ultrastructure of Tissue Barriers and Synthesis of Anti-Infectives Designed to Penetrate Them.
MISTLBERGER k1, KREMSER C2, paschkunova I3, SÖLDER e4, WIESER E1, GALANSKI M3, BARTSCH g5, Keppler B3, JASCHKE W2, Hugl B6, Buchberger W7, TALASZ h8 & Debbage P1
Depts. 1Histol. Mol. Cell Biol., 2Radiol., 6Vasc. Surg., Clinical Chem. Biochem.; Clinics of 4Ob. Gyn., 5Urol., Medical Univ.; 7Tirol Land Hosp. Innsbruck, Austria; 3Inst. Inorg. Chem., Univ. Vienna, Austria.

389	A New Class of Potent Dual Acting Gyrase and Topoisomerase IV Inhibitors.
OLSON E1, CHARIFSON P1, GRILLOT A-L1, GROSS C1, GROSSMAN T1, MANI N1, MOORE J1, NICOLAU D2, PARSONS J1, STAMOS D1, TESSIER P2,
1Vertex Pharmaceuticals Inc., Cambridge, MA, U.S.A; 2Hartford Hospital, Hartford, CT, U.S.A.

569	A novel tetramethylpiperidine-substituted phenazine (B4125) with activity against multiple drug-resistant Gram-positive bacteria.
VAN RENSBURG CEJ1,  O’SULLIVAN JF 2, HUYGENS F3.
1University of Pretoria, Pretoria, South Africa, 2University College Belfield, Dublin, Ireland, 3Queensland University of Technology, Brisbane, Queensland.

047	Antifungal and Antimycobacterial Activity of New Imidazole and Triazole Derivatives. A Combined Experimental and Computational Approach.
ZAMPIERI D1, MAMOLO MG1, VIO L1, FERRONE M2 , PRICL S2, SCIALINO G3, and BANFI E3
1Dept of Pharmaceutical Sciences; 2Dept of Chemical, Environmental and Raw Materials Engineering; 3Dept of Biomedical Sciences Microbiology Sect, University of Trieste, Trieste, Italy.

052	Predicting In-Vitro Permeability of Antimycotics Using Quantitative Structure-Activity Relationship (QSAR) Models.
BASAK SC, MILLS D
Natural Resources Research Institute, University of Minnesota Duluth, Duluth, MN, USA.

Friday, September 10, 2004

Category:	Mechanisms of pharmacological and biochemical action of antiinfectives

07:30 - 09:30 AM	Room assignment will be printed in the final program

491	The Role of Efflux Transporters in Drug Targeting.
SEELIG A
Biozentrum der Universität Basel, Basel, Schweiz.

334	Exploitation of Peptide and Amino Acid Permeases as Drug Transporters of Antifungals.
MILEWSKI M
Gdańsk University of Technology, Gdańsk, Poland.

113	The Mode of Action of Glutathione Peptides as Antiprotozoal Agents.
D’SILVA C1, DAUNES S1; TOMAS A2 ; ALIBU V P3, CLAYTON C3
1Department of Chemistry & Materials, Manchester Metropolitan University, John Dalton Building, Chester Street, Manchester, UK; 2 Department of Molecular Immunology, Instituto for Molecular and Cell Biology, Porto, Portugal; 3ZMBH, Universitat Heidelberg, Heidelberg, Germany.

152	Kit for Instant Tc-99m Labeling of the Antimicrobial Peptide Ubiquicidin 29-41: A Specific Radiopharmaceutical for Bacterial Infection Imaging.
FERRO-FLORES G1, ARTEAGA-MURPHY C2, PALOMARES-RODRIGUEZ P1, MELENDEZ-ALAFORT L3, PEDRAZA-LOPEZ M2
1Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, México; 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, DF, México; 3Universidad Autónoma del Estado de México, México.

205	Infectomics: Creating Holistic Strategies for the Development of Antiinfectives against the Central Nervous System (CNS) Infection.
Huang SH1,2, ZENG FY2, JONG A1, WU CH1, Huang SZ2
1Childrens Hospital Los Angeles University of Southern California, Los Angeles, USA; 2Shanghai Children’s Hospital Shanghai Jiao Tong University, Shanghai, China.

343	Effect of Isoniazid (INH) on Viability, Cell Morphologies and Acid-fastness Properties of Mycobacterium avium NCTC 8559 During the Growth Cycle.
MOHAMAD S1, IBRAHIM P2
1School of Biological Sciences, Universiti Sains Malaysia , Penang, Malaysia; 2 School of Pharmaceutical Sciences, Universiti Sains Malaysia , Penang, Malaysia.

482	Focus on Albendazole for Echinococcosis.
Hans G. SCHIPPER
Academic Medical Center, Amsterdam, The Netherlands.

261	Limitations of Virtual Screening: Experimental and Computer-Aided Search for Novel Inhibitors of E. coli Methionine Aminopeptidase.
SCHIFFMANN R, KLEIN CD
FR 8.2 Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany.

Category:	Clinical studies and use of antibiotics

07:30 - 09:30 AM	Room assignment will be printed in the final program

149	First Line Helicobacter pylori Therapy – are Commonly Used Regimens the Most Appropriate Ones? A Review.
FARUP PG
Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, and Innlandet Hospital HF, Gjøvik, Norway.

316	Effect of Helicobacter Pylori (HP) Eradication in the Clinical Course of Recurrent Aphthous Stomatitis (RAS).
MARKOPOULOS AK
Aristotle University of Thessaloniki, Dept.of Oral Medicine and Maxillofacial Pathology, Thessaloniki, Greece.

326	EFFECTIVENESS OF ANTIINFECTIVES.
Ramona Mc Loughlin, Colm O’Morain
Adelaide & Meath Hospital, and Trinity College Dublin, Dublin.

010	Pattern of Antibiotic Therapy and Clinical Outcome in Acute Generalized Peritonitis in Semi-Urban and Rural Nigerian Community.
ADESUNKANMI A.R. K, BADMUS T.A, AGBAKWURU E.A.
Department of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile-Ife. Nigeria.

086	Reasons for Failure of Antibiotic Treatment in Patients with Pyogenic Liver Abscess (PLA).
CERWENKA H
Division of Visceral Surgery, Department of Surgery, Medical University of Graz, Austria.

498	A Prospective Study of  Comparison of Efficacy of Two Combination Treatment Groups in Syndromic Treatment of Lower genital infections.
SHARMA JB 1, MITTAL S1, RAINA U2
1 All India Institute of Medical Sciences, New Delhi, India; 2 Lok Nayak Hospital, New Delhi, India.

574	Is Antiinfective Therapy the “Magic Bullet” in the Prevention of Preterm Delivery?
Vidaeff A
Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Medical School at Houston, Houston, USA.

412	Antibiotic treatment of acute pyelonephritis: are we asking the right questions?
MEZZA E1, BURDESE M1, COLLA L1, CONSIGLIO V1, TATTOLI F1, MADDALENA E1, SEGOLONI GP1, PICCOLI G1, PICCOLI GB1.
Chair of Nephrology, Internal Medicine Department, University of Turin – Italy.

Category:	Pharmacokinetics and tissue penetration of antiinfectives

07:30 - 09:35 AM	Room assignment will be printed in the final program

112	Dose Adjustment of Ciprofloxacin in Renal Failure: Should we Reduce the Dose or Prolong the Administration Interval?
CZOCK D, KELLER F
University Hospital Ulm, Ulm, Germany.

124	Metabolism of Metronidazole in Early Stages of Chick Embryo - A Novel Model for Human Metabolism.
DEVARAKONDA R K, NARASAIAH N AND  VIDYASAGAR J
Cancer, Aging & Metabolism Research Division, Kakatiya University, University College of Pharmaceutical Sciences, WARNGAL, AP, India.

080	Tissue Penetration of Anti-infective Agents.
	BROWN PD
Department of Basic Medical Sciences, Biochemistry section, University of the West Indies, Mona, Kingston, Jamaica.

209 	Penetration of Anti-infectives into the Lung.
HUSSAIN, I and AMIN, MZ
Washington University St. Louis, MO USA.

330	Azithromycin (AZT) serum and mammary secretion concentrations after its intramammary (IMM) administration in healthy and mastitic cows.
MESTORINO N, TURIC E, PESOA J, ERRECALDE JO.
Department of Pharmacology. Facultad de Ciencias Veterinarias. Universidad Nacional de La Plata.

366	Antibiotic penetration of the blood-brain barrier pharmacokinetics in cerebrospinal fluid and neurotoxicity (Review).
Mirjana Nesin
Weill Medical College of Cornell University, New York City, N.Y., USA.

	Tissue concentrations - what  does it matter from a clinical point of view?
Scaglione F.
University of Milan, Milan, Italy.

368	Extended Interval Dosing of Aminoglycosides in Neonates is Safe and Effective: Systematic Review and Meta-Analysis of Controlled Trials.
NESTAAS E1, BANGSTAD HJ2, SANDVIK L2, WATHNE KO2
1Hospital of Vestfold, Tønsberg, Norway, 2Ullevål University Hospital, Oslo, Norway.

Category:	Antiinfectives - new and known synthetic compounds

07:30 - 08:45 AM	Room assignment will be printed in the final program

554	Search For A New Chemical Class Of Metallo-b-Lactamase Inhibitors: Reversing Bacterial Antibiotic Resistance.
TONEY JH, THOMAS, JD, MOLOUGHNEY, JG
Department of Chemistry and Biochemistry, Montclair State University, Upper Montclair, New Jersey, USA.

137	The Use of Antibiotics in Immobilized Form: A Controlled Drug Delivery System to Minimize the Risk of Drug Misuse/Misdose in Developing Countries.
El Enshasy, H.A.
Mubarak City for Scientific Research, Alexandria, Egypt.

188	Design and Synthesis of Contact System Inhibitors for the Treatment of Infectious Diseases.
RUSSELL, W1, FEX, T2, BJÖRCK, L1 and HERWALD, H1
1Section for Molecular Pathogenesis, Department of Cell and Molecular Biology, Lund University, Sweden and 2Orbichem, Lund, Sweden.

210 	New Anti-infective Agents Developed by Novel Chemo-combination Strategy.
HWU JR1, TSAY S-C2
1National Tsing Hua University, Hsinchu, Taiwan, R.O.C.; 2Well-being Biochemical Corporation, Taipei, Taiwan, R.O.C.

363	Metal Complexes as Leishmanicidal Agents.
aNAVARRO M, aCISNEROS-FAJARDO E, bMARCHAN E.
aI.V.I.C. Centro de Química. Caracas. BIICA-U.D.O. Cumaná Venezuela.

Category:	Antineoplastic agents - new and known synthetic compounds

07:30 - 09:20 AM	Room assignment will be printed in the final program

244	Antitumor Active Metal Coordinated Compounds - New Concepts For Cancer Cemotherapy - A Review.
KEPPLER BK
Institute of Inorganic Chemistry, University of Vienna, Vienna, Austria.

030	Reactions of Potent Anti-Tumour Complex trans-[RuIIICl4(ind)2] with DNA-Relevant Nucleobase and Thioethers: an Insight into Biological Action.
ARION VB, EGGER A, REISNER E, CEBRIAN-LOSANTOS B, KEPPLER BK
Institute of Inorganic Chemistry of the University of Vienna, Austria.

183	Investigations into the Mechanism of Action of indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III) – an Antineoplastic Ruthenium(III) Coordination Compound.
HARTINGER CG, SCHLUGA P, EGGER A, PONGRATZ M, ARION VA, JAKUPEC MA, GALANSKI M, KEPPLER BK
Institute of Inorganic Chemistry, University of Vienna, Vienna, Austria.

256	DNA Cleavage Activity of Diazonium Salts.
KIZIL M1, INCE YILMAZ E2, PİRİNÇÇİOĞLU N1, AYTEKİN Ç1, KIZIL G1
1Department of Chemistry, 2Department of Biology, Faculty of Science, Dicle University, Diyarbakır, Turkey.

401	STI 571 Bullets Ionizing Radiation in HNSCC.
Francisco S. Pardo, Weg Okenko, Joseph Aguilera, Jamie Milligan, Jean Wang
Departments of Biology, Radiation Biology, Otolaryngology, and Radiation Oncology. University of California, San Diego, and the Moores UCSD Cancer Center, San Diego, CA  USA.

101	Inhibition of cyclo-oxygenase 2 (COX-2) enzyme in breast cancer.
CHOW LWC
Hung Chao Hong Integrated Centre for Breast Diseases, University of Hong Kong Medical Centre, Hong Kong, China.

175	Are 2’-deoxyadenosine esters potential antileukemic drugs?
GRIEB P1,KRYCZKA T1,ANDRZEJEWSKA M2,STACHNIK K3, KAZIMIERCZUK Z1.
1Department of Experimental Pharmacology, Mossakowski MRC PAS, Warsaw, Poland; 2Institute of Chemistry, Agricultural University, Warsaw, Poland; 3Laboratory of Flow Cytometry, National Institute of Public Health, Warsaw, Poland.

Category:	Antivirals & Antifungals - clinical studies

07:30 - 09:45 AM	Room assignment will be printed in the final program

432	Combined Antiviral and Anti-inflammatory Therapy of Viral Pneumonia.
PRINCE GA1, BOUKHVALOVA M1, BLANCO J1
1Virion Systems, Inc., Rockville, Maryland, USA.

272	Antiviral maintenance therapy with interferon- 2b and ribavirin for recurrent hepatitis C after liver transplantation-----clinical and morphological benefits in the long-term follow-up.
A. Kornberg, B. Küpper, A. Tannapfel, M. Hommann, U. Settmacher, J. Scheele.

042	Oral Valacyclovir Treatment in Herpetic Corneal Disease.
AVUNDUK AM, SÖZEN E, AKYOL N
Karadeniz Technical University, School of Medicine, Department of Ophthalmology. Trabzon-Turkey.

120	In-vivo Monitoring of Herpes Simplex Virus type 1 (HSV) Encephalitis with Positron Emission Tomography (PET).
BUURSMA AR1, KLEIN HC2, GARSSEN J3, KEGLER D3, HOSPERS GAP1, VAALBURG W1, DE VRIES EFJ1
1Groningen University Hospital, Groningen, the Netherlands; 2Centre for Mental Health Winschoten, Winschoten, the Netherlands; 3National Institute for Public Health, Bilthoven, the Netherlands.

487	Use of HIV-1 p24 Antigen for Monitoring Continuous and Structured Antiretroviral Therapies and Implications for Therapeutic Vaccination.
SCHUPBACH J 
Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland.

238	Prevention of Invasive Candida Infection in High-Risk Preterm Infants <1000 Grams Birth Weight.
D Kaufman, R Boyle, KC Hazen, JT Patrie, M Robinson and LB Grossman
University of Virginia, Charlottesville, VA. USA.

472	SHOULD WE THINK FUNGUS IN POLYSYMPTOMATIC PATIENTS ?
A randomised, double-blind trial with nystatin versus placebo in general practice
Santelmann H, Lærum E, Rønnevig J and Fagertun HE
Institutt for Allmennmedisin og Samfunnsmedisin, Universitet i Oslo, Norge.

211	Antiinfectives Used for Penicillium marneffei Infection in HIV-Infected Patients: a Review.
IAMAROON A1, PONGSIRIWET S1, THOSAPORN W1, VANITTANAKOM N2
1Department of Odontology and Oral Pathology, Faculty of Dentistry; 2Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

347	Early Treatment of Candidiasis in Non-Neutropenic Critically Ill Patients.
NOLLA-SALAS M1, MONMANY J2, GICH I3, IBÀÑEZ-NOLLA J4
1Institut de Recerca*. Emergency Department, Hospital de l’Esperit Sant, Santa Coloma de Gramenet, Barcelona; 2Internal Medicine Department*; 3Department of Epidemiology*; 4Emergency Department, Hospital General de Catalunya, Sant Cugat del Vallès, Barcelona. *Hospital de Sant Pau, Universitat Autònoma de Barcelona. Barcelona. Spain.

Category:	Pharmacodynamics and experimental therapy of antiinfectives

08:00 - 09:30 AM	Room assignment will be printed in the final program

146	The Importance of Pharmacokinetic/Pharmacodynamic (PK/PD) Knowledge Discovery in the Development of Antiinfective Agents.
Ette EI, Chu H-M, Ajayi FO2.
Vertex Pharmaceuticals, Cambridge, MA., U.S.A., 2Proctor and Gamble, Pharmaceuticals Division, Cincinnati, OH., U.S.A.

212	FROM MAGIC BULLETS TO NANOTECHNOLOGY – WE HAVE COME A LONG WAY AND YET A LONG WAY TO GO FOR  EFFECTIVE MANAGEMENT OF INFECTIOUS DISEASES.
Omer Iqbal, MD, FACC., Jawed Fareed, Ph.D, FACB.
Department of Pathology, Loyola University Medical Center, Maywood, IL, USA.

064	Correlation between antibiotic pharmacokinetics and antibiotic resistance.
E Bergogne-Berezin
Bichat University, Masson, Paris, France.

174	Intracellular Penetration and Activity of Levofloxacin in Staphylococcus Aureus Infected Human Monocytes.
GRELLET J1, NGUYEN H1, SAUX MC1, QUENTIN2
1Pharmacokinetics Laboratory, 2Microbiology Laboratory, Bordeaux II University, Bordeaux, France.

235	Distribution of Metronidazole (MDZ) in Muscle Tissue of Healthy Volunteers (H) and Patients with Septic Shock (SS) and its Efficiency Against Bacteroides fragilis (Bf) in Vitro.
KARJAGIN J, PÄHKLA R, KARKI T, STARKOPF J
University of Tartu, Tartu, Estonia.

298	Non-antibiotic treatment of infections – some alternative strategies.
LJUNGH Å
Dept Medical Microbiology, Dermatology and Infection, Lund University, Lund, Sweden.

Category: 	Pharmacokinetics and tissue penetration of antiinfectives

08:50 - 10:35 AM	Room assignment will be printed in the final program

621	Dosing Strategy for Antiinfectives in First-In-Human (FIH) Studies.
ZHU M
Clinical Drug Evaluation, Johnson & Johnson Pharmaceutical Research and Development LLC, New Jersey, USA.

644	Use of Modelling and Simulation in the development of Levofloxacin.
WEBER W, RUEPPEL D
Aventis Pharma Deutschland GmbH, Germany.

285	Influence of Sex on the Pharmacokinetics of Chosen Quinolone.
LAMPARCZYK H, KONIECZNA L, CHMIELEWSKA A
Medical University of  Gdańsk, Gdańsk, Poland.

028	Amoxicillin (AMX) Clinical Pharmacokinetics (PK): past, present, and future.
ARANCIBIA A
Department of Pharmaceutical Sciences, University of Chile, Santiago, Chile.

479	Pharmacokinetics and efficacy of old and new antifungal agents for the treatment of endogenous endophthalmitis.
SCHELENZ S
Norfolk & Norwich University Hospital, Norwich, United Kingdom.

575	Targeting of Amphotericin B using Lipid Nanospheres for the Treatment of Visceral Leishmaniasis.
VOBALABOINA V1, VEERAREDDY PR1, AND ALI N2.
1.University College of Pharmaceutical Sciences, Kakatiya University, Warangal, A.P-INDIA.
2. Indian Institute of Chemical Biology,Jadavpur, Kolkata, INDIA.

199	Pharmacokinetics and effects of ribavirin by intravenous and intraventricular administration for the treatment of subacute sclerosing panencephalitis (SSPE).
Mitsuaki Hosoya1, Hitoshi Suzuki1, Shuichi Mori2, Shiro Shigeta2
1Department of Pediatrics and 2Department of Microbiology, Fukushima Medical University School of Medicine.

Category:	Diagnostic tests in cancer / adverse events of cancer treatment & Adverse events of antineoplastic compounds

09:45 - 10:45 AM	Room assignment will be printed in the final program

247	Enhancing the “Magic Bullet”: Bispecific antibody-polymer probe technology for gamma imaging of small vascular lesions in vivo.
KHAW BA1, TEKABE Y1, DONAHAY T2, JOHNSON LL2.
1Northeastern University, Boston, MA, USA, 2Rhode Island Hospital, Providence, RI, USA.

384	Prognostic and Predictive Biomarkers in Breast Cancer.
O’DRISCOLL L1, KENNEDY SM2, CROWN J1&2, CLYNES M1
1National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; 2St Vincent’s University Hospital, Dublin 4, Ireland.

257	The Protective Effect of Melatonin on Cisplatin Ototoxicity.
Ahmet Kizilay1, M. Tayyar Kalcioglu2, Mustafa Iraz3, Ercument Olmez4, Mucahit Egri5, Orhan Ozturan6
1,2,6 Department of Otorhinolaryngology; 3,4Department of Pharmacology; 5Department of Public Health; Inonu University School of Medicine, Malatya, TURKEY.

328	Intestinal permeability (IP) in the assessment of intestinal toxicity of cytotoxic drugs.
Melichar B, Dvořák J, HyšpLer R, Zadák Z
Charles University Medical School, Hradec Králové, Czech Republic.

Category:	Antiinfectives - new and known non-synthetic compounds

09:45 - 11:00 AM	Room assignment will be printed in the final program

079	The Magic Bullet Nisin: Structural Insights and an Additional Mechanism of Action?
Breukink E1, Hasper H1, Hsu, S-T D2
1Department of Biochemistry of Membranes and 2Department of NMR Spectroscopy Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands.

545	Nontoxic, antifungal plant defensins interact with fungal-specific sphingolipids.
THEVISSEN K1, WARNECKE DE2, FRANCOIS IEJA1, AERTS A1, LEIPELT M2, HEINZ E2, CAMMUE BPA1
1CMPG, K.U. Leuven, Kasteelpark Arenberg, Heverlee, Belgium; 2Institut fur Allgemeine Botanik, University of Hamburg, Hamburg, Germany.

526	Antimycobacterial and Antiplasmodial Activities of Curcuminoids and Analogues: Structure-activity Relationship Studies.
CHANGTAM C1, THONGON N2, SAENBOONRUENG J2, SUKSAMRARN A1
1Ramkhamhaeng University, Bangkok, Thailand; 2National Center for Genetic Engineering and Biotechnology, Pathumthani, Thailand.

445	Eukaryotic antibiotic peptides as leishmanicidal agents. The target is not always the parasite.
RIVAS L1, LUQUE-ORTEGA  JR1; SAUGAR JM1, DEL SOL V 2, MENÉNDEZ R3., VALENZUELA C4. FRESNO M.2, MIRAS MT3, ANDREU D5.
1Centro de Investigaciones Biológicas (CSIC) Madrid. 2 Centro de Biología Molecular (CSIC-UAM) Madrid (Spain), 3 Facultad de Veterinaria , UCM. Madrid, 4 Instituto de Farmacología (CSIC-UCM) Madrid (Spain). 5 Universitat Pompeu Fabra , Barcelona  (Spain).

425	In vitro leishmanicidal activity of naphthylisoquinoline alkaloids.
Ponte-Sucre, A1,3, Gronauer, T.2, Newman, S. 2, Faber, J.2, Bringmann, G. 2  Moll, H.1
1Institut für Molekulare Infektionsbiologie, Universität Würzburg, Germany, 2 Institut für Organische Chemie, Universität Würzburg, Germany and 3Laboratorio de Fisiología Molecular, IME, Universidad Central de Venezuela.
Category:	Mechanism of tumor development and growth

10:00 AM - 12:15 PM	Room assignment will be printed in the final program

339	TUMOR ANGIOGENESIS: KEY ROLE OF INTEGRINS.
Francesc Mitjans
Laboratorio de Bioinvestigación, Merck Farma y Química, S.A.

437	Cytoskeletal Actin Remodeling – A Potential Target for Cancer Therapy and Prevention.
	JIANYU RAO1
1Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles.

624	Effect of circadian rhythm scrambling on toxicity and survival of tumor-bearing mice.
	Alex Zvulunov,a,b Leah Peleg,b,c Rachel Carlebach,b Israel E. Ashkenazi.b
From aDivision of Pediatric Dermatology, Schneider's Children Medical Center, Petah-Tiqva, the bChronobiology Unit, Department of Human Genetics, Sackler School of Medicine, Tel Aviv University, Tel-Aviv, and cDanek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

438	Malignant Transformation of Syrian hamster embryo cells by Malachite green is Associated with Abrogation of Cell Cycle Checkpoint Controls and Increased Expression of P38 MAP Kinase.
	RAO KVK, BIPASHA BOSE
Chemical Carcinogenesis Group, Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India.

094	Application of Expression Genomics in Predictive and Personalized Medicine:  Magic Gene Expression Profiles.
	CHIN KV1,3, WONG YF2, LIN W3
1Susan Lehman Cullman Laboratory for Cancer Research and Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ; 2Department of Obstetrics and Gynecology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong; 3Imhoteq Co., Highland Park, NJ.

341	Tumor Hypoxia and Hypoxia-regulated Genes as Targets for Novel Anticancer Chemotherapy Strategies; Building on the Legacy of Paul Ehrlich and Otto Warburg.
	AIRLEY RE1, MOBASHERI A2
1Tumor Metabolism and Therapeutics Research Group, School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, United Kingdom
2Molecular Pathogenesis and Connective Tissue Research Groups, Department of Veterinary Preclinical Sciences, University of Liverpool, Liverpool, United Kingdom.

550	a-Tocopheryl succinate enhances the cytotoxic effect of immunological and chemotherapeutic agents.
	Tomasetti M1, Alleva R2, Benassi MS3, Neuzil J4, Borghi B2, Procopio A1
1Department of Molecular Pathology and Innovative Therapies, Ancona, Italy; 2Department of Anesthesiology, Bologna, Italy; 3Laboratory of Oncology, Bologna, Italy; School of Health Sciences, Southport, Queensland, Australia.

222	The mechanisms of all-trans retinoic acid and arsenic trioxide-induced disease remission of acute promyelocytic leukemia.
Yongkui Jing
Division of Hematology/Oncology, Department of Medicine, Mount Sinai Schoo of Medicine, New York, NY, USA.

641	Mechanisms of epigenetic silencing in leukemias.
	M. Buschbeck, A. Gutierrez, I. Joval, L. Morey, R. Villa and L. Di Croce
Center for Genomic Regulation, Barcelona, Spain.

Category:	In vitro action of antimalarials

10:45 AM - 12:30 PM	Room assignment will be printed in the final program

061	NOVEL NATURAL ANTIMALARIALS FROM PLANTS.
Benoit-Vical F
1Laboratoire de Chimie de Coordination du CNRS, 2Laboratoire de Parasitologie-Mycologie, CHU Rangueil, Toulouse Cedex, France.

153	Novel Options of Anti-malarials Based on Sphingolipid Metabolism and Ceramide Cytotoxic Activity.
Flescher E1, Pankova-Kholmyansky I2
1Tel Aviv University, Tel Aviv, Israel; 2Weizmann Institute of Science, Rehovot, Israel.

225	Critical Review of Methods for the Measurement of Antimalarial Drugs Activity.
Jouin H1,2
1 Inserm U 547 Institut Pasteur, Lille, France
2 Unité d’Immunologie Moléculaire des Parasites, Institut Pasteur, Paris, France.

458	Malaria Vectors of Anopheles Hyrcanus Group in Korea and Other Asian Countries:  Distribution, Habitats, Morphology and Molecular Characterization.
RUEDA, L. M.1
1Walter Reed Biosystematics Unit, WRAIR/Smithsonian Institution, Suitland, MD, USA.

502	Anti-adhesive peptides and antibodies as potential therapeutics for falciparum malaria.
SHERMAN IRWIN W., WINOGRAD, ENRIQUE
University of California, Riverside, CA, USA.

567	Synergistic “Magic Bullet” Chemotherapy Effective Against Multiple Drug Resistant Malaria and Cancer In Vivo.
VAN DYKE K (1) and YE Z (2)
Biochemistry and Molecular Pharmacology, West Virginia University, Medical Center, Morgantown, WV, USA (I) and Academy of Traditional Chinese Medicine Beijing, China (2) and Cancer Biologics of America International Inc. (I).

591	Antimalarial Drug Resistance in Plasmodium falciparum – a Host of Challenges.
Wernsdorfer WH1,2, Wernsdorfer G2
1Division of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria; 2Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Category:	Mechanisms of pharmacological importance

11:15 AM - 01:00 PM	Room assignment will be printed in the final program

592	Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation.
Wetzler M
Roswell Park Cancer Institute, Buffalo, NY, USA.

020	Interaction of Transported Drugs with the Lipid Bilayer and P-glycoprotein: Drug Transport is Mediated by a Solvation Exchange Mechanism.
OMOTE H, AL-SHAWI MK
University of Virginia Health System, Charlottesville, VA, USA.

053	Flow cytometry for the measurement of phagocyte functions.
BASSØE C-F
Medical Department, Haukeland University Hospital, Bergen, Norway.

155	S100A6 and CacyBP/SIP – Two Proteins Identified in Ehrlich Ascites Tumor Cells Potentially Involved in Degradation of β-Catenin.
FILIPEK A
Nencki Institute of Experimental Biology, Warsaw, Poland.

141	Ploidy cycles in tumours: A reproductive pathway?
ERENPREISA JE1, CRAGG MS2, IVANOV A1,2, KALEJS M1, LIEBE B3, SCHERTHAN H3, ILLIDGE TM3
1Latvian University Biomedical Research and Study Centre, Riga, Latvia; 2Cancer Science Division, Southampton University, United Kingdom; 3MPI for Molecular Genetics, Berlin, Germany.

195	Glutamine (GLN) – Magic Bullet in Treatment of Protein Wasting in Severe Illness.
HOLECEK M
Department of Physiology, Charles University School of Medicine, Hradec Kralove, Czech Republic.

177	Regulation of Renal Bicarbonate Transport: The Role of Sodium Bicarbonate Cotransporter – Carbonic Anhydrase Interaction.
GROSS E
Case Western Reserve University, Cleveland, OH, USA.

Category:	Targeted delivery of antineoplastic agents

11:15 AM - 12:30 PM	Room assignment will be printed in the final program

276	Prodrugs in Cancer Chemotherapy – An Overview of Active and Passive Targeting Strategies.
Kratz F
Tumor Biology Center, Freiburg, Germany.

243	Lipidic carriers of siRNA: differences in the formulation, cellular uptake and delivery with plasmid DNA.
Sebastien Spagnou, Andrew D. Miller and Michael Keller
IC-VEC Ltd, London, UK.

151	Nanoparticles of Biodegradable Polymers for Cancer Chemotherapy.
	FENG SS
Department of Chemical & Biomolecular Engineering and Department of Bioengineering, National University of Singapore.

180	Superparamagnetic Iron Oxide Nanoparticles as Magic Bullets for Cell Targeting.
GUPTA AK1, GUPTA M2
1Crusade Laboratories Limited, Southern General Hospital, Glasgow, U.K.; 2Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, U.K.

018	Targeted Therapeutics in the Treatment of Cancer.
ALLEN, TM1, PONZONI, M2, PASTORINO, F2, SAPRA, P1
1Pharmacology, Univ. Alberta, Edmonton, Canada; 2G. Gaslini Children’s Hospital, Genoa, Italy.

Category:	Analytical techniques

12:30 - 01:45 PM	Room assignment will be printed in the final program

	The use of capillary electrophoresis to determine counterfeit antibiotics.
HOLZGRABE U
Institute of Pharmacy and Food Chemistry, University of Wuerzburg, Germany.

640	IMMUNOAFFINITY CAPILLARY ELECTROPHORESIS AS A TOOL FOR EARLY DIAGNOSIS OF SEPTIC SHOCK AND AS A POTENTIAL SCREENING TEST IN ITS PROGNOSIS.
Norberto A. Guzman
Bioanalytical Drug Metabolism, Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey, USA.

226	Use of Enzyme Linked Immunoserbent Assay (ELISA) for the Diagnosis of Clinically Suspected Reffered Human Cystic and Alveolar Hydatidosis Cases in Nepal.
D.D. Joshi, Mahendra Maharjan, Harish Joshi, P.B. Chand
National Zoonoses & Food Hygiene ResearchCentre (NZFHRC), Chagal, Kathmandu, Nepal.

604	Detection of Leptospira Agglutination by using Flow-Cytometry Light Scatter Analysis:  A New Approach for Serological Testing for Leptospirosis.
YITZHAKI S 1, ZAHAVY E1, BARNEA A 1, KEYSARY1 A
Israel Institute for Biological Research Ness-Ziona, Israel.

Category:	Role of cells and their staining by dyes

12:40 - 02:35 PM	Room assignment will be printed in the final program

311	Location, Orientation and Dynamics of Fluorescent Dyes in Lipid Bilayer Membranes.
Krishna MMG1,2, Periasamy N1
1Tata Institute of Fundamental Research, Mumbai, India; 2University of Pennsylvania School of Medicine, Philadelphia, USA.

296	Differential Cytoprotective Activity of Carboxyfullerene.
LIN H-S¹, LIN T-S¹, D’ROSARIO T¹, LUH T-Y²
¹Washington University, St. Louis, MO, USA, ² National Taiwan University, Taipei, Taiwan.

559	The clinical and therapeutic relevance of cytokeratin immunostaining of metastastatic adenocarcinomas.
Tot T
Department of Pathology and Clinical Cytology, Central Hospital, Falun, Sweden.

348	The Role of the Eosinophil in Health and Disease.
1Moqbel R., 1Odemuyiwa S.O., 2Adamko D., 3Ghahary A.
Departments of Medicine1, Pediatrics2 and Surgery3, University of Alberta, Edmonton, Alberta, CANADA.

566	Mast cells and mastocytosis: From Paul Ehrlich to the current millennium.
	Peter Valent
Department of Internal Medicine I
Division of Hematology & Hemostaseology
Medical University of Vienna, Austria.

600	Using microencapsulated iNOS-expressing cells as an ‘artificial macrophage’ to combat the infectious microbes and cancer.
WEIMING XU &  LIZHI LIU
Wolfson Institute for Biomedical Research, University College London.

588	Mitochondria-Targeted Bolasomes as “Magic Bullets” on the Subcellular Level.
WEISSIG V
Northeastern University, Bouve College of Health Sciences, School of Pharmacy, Department of Pharmaceutical Sciences, Boston, MA, USA 340.

Category:	Antineoplastic agents - new and known synthetic compounds

12:45 - 02:30 PM	Room assignment will be printed in the final program

415	More bullets against carcinomas: MUC1 epitopes, Flt3 ligand (Flt3L) and Pluronic block copolymers (PBC).
PISAREV VM1, KINARSKY L1, CAFFREY T1, HANISCH F-G2, von MENSDORF-POUILLY S3, KABANOV A, Hollingsworth MA1, SHERMAN S1
1Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; 2Instutute of Biochemistry, Medical faculty, and Central Bioanalytics of the Center of Molecular Medicine, University of Cologne, Germany; Dept. of Obstetrics and Gynaecology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.

186	Molecular Mechanism of Antitumour Effect of Diospyrin and Derivatives.
HAZRA B1, DAS SARMA M1, KUMAR B1, DAS K1, PANDEY BN2, MISHRA KP2
1Jadavpur University, Calcutta, India; 2Bhabha Atomic Research Centre, Mumbai, India.

203	Drug Design of BPR0L075 as an Anti-Cancer Agent.
Hsing-Pang Hsieh1; Jing-Ping Liou1; Chun-Wei Chang1; Ching-Chuan Kuo2; Yi-Ling Chang1; Fu-Ming Kuo1; Huan-Yi Tseng1, Wen-Yu Pan2; Ching-Ping Chen1; Yung-Ning Yang1, Chiung-Tong Chen1, Shiow-Ju Lee1, Jang-Yang Chang2
1Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei, Taiwan; 2Divisions of Cancer Research, National Health Research Institutes, Taipei, Taiwan.

337	Oxazaphosphorinane Drugs. New Analogues and Metabolic Studies and New Therapeutic Approaches.
Konrad Misiura
Department of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Lodz, Poland.

614	Benefit of liposomes prepared from alkylphospholipids for the treatment of cancer.
ZEISIG R, WALTHER W, FICHTNER, I.
Max Delbrück Center for Molecular Medicine Berlin-Buch, Germany.

172	The Xc- Cystine/Glutamate Antiporter as an Anticancer Target - Evaluation of the Azocompound, Sulfasalazine (SASP).
GOUT PW, WANG YZ
BC Cancer Agency, Vancouver, Canada.

630	Amonafide: Past, Present and Future.
BraÒa MF1
Universidad San Pablo-CEU, Madrid, Spain.

Category:	Targeted delivery of antineoplastic agents

12:45 - 02:20 PM	Room assignment will be printed in the final program

	Pharmacokinetics of high-molecular anticancer agents
Kloft C
Freie Universitaet Berlin, Institute of Pharmacy, Berlin, Germany.

284	Targeted drug delivery via reconstituted high density lipoproteins (rHDL).
LACKO AG , NAIR, M. PARANJAPE S, MOOBERRY L, McCONATHY, WJ
University of North Texas Health Science Center, Fort Worth, TX.

494	The Use of Modified Forms of the EGF Receptor Binding Fragment for Targeted Drug Delivery to Cancer Cells.
SEVERIN S.E., FELDMAN N.B., LUTSENKO S.V
Research Institute of Medical Ecology, Moscow, Russia.

510	Targeted Delivery of Chemotherapy Drugs via a Prostate Specific Antibody Induces Apoptosis and Inhibits Cell Proliferation in Human Prostate Cancer Cells in vitro and Their Tumors in Nude Mice.
SINHA AA1, 2, 4, WILSON MJ2, 3, 4, REDDY PK2, PRETLOW TG5
1Depts. of Genetics, Cell Biol. & Develop., 2 VA Research Service, 3Lab. Med. & Pathol., 4Cancer Center, Univ. of Minnesota, Minneapolis, MN, and 5Institute of Pathol., Case Western Reserve Univ., Cleveland, Ohio, USA.

132	Microdosimetry and Intratumoral Localization of Intravenously Administered 131I Labelled Monoclonal Antibodies (mAb) are critical to successful Radioimmunotherapy (RIT) of lymphoma.
DU Y, JOHNSON P, GLENNIE M, ILLIDGE T
Cancer Sciences Division, University of Southampton, UK.

164	Identification of Target Genes in Oncology – The Genomic Approach.
GeBAUER G (1+2), Krones-Herzig A (2), Glinsky G (2), McClelland M(2)
(1) Department of Cell and Molecular Biology, Sidney Kimmel Cancer Center, San Diego, CA, USA; (2) Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany.

Category: 	Antimalarial compounds - clinical studies

01:30 - 03:00 PM	Room assignment will be printed in the final program

108	Double-blind randomised controlled trial of malaria chemoprophylaxis in British soldiers, with extended follow-up.
Croft AM, von Bertele MJ, Brutus EC
Headquarters British Forces Germany Health Service, Mönchengladbach, Germany.

265	Relationship of Parasite Count Dropping Rate and Clinical Outcome in Severe Falciparum Malaria.
K H KOH, P H CHEW.
Sarawak General Hospital, Malaysia.

264	Hepatic dysfunction and hepatic encephalopathy in malaria.
KOCHAR DK, AGARWAL P, KOCHAR SK, JAIN R, RAWAT N, POKHARNA RK, KACHHAWA S, SRIVASTAVA T
S.P. Medical College, Bikaner – India.

637	Malaria Control Trials by Transmission Blocking with Primaquine.
ISHII A
Jichi Medical School, Tochigi, Japan.

227	Toxicity of Antimalarial Drugs: A review.
HUSSIEN O. ALKADI
Faculty of Medicine and Health Sciences, Sana’a University, Republic of Yemen.

434	Malaria Control – Prospects.
Raghunath, D.
Sir Dorabji Tata Centre for Research in Tropical Diseases Innovation Centre, Indian Institute of Science Campus, Bangalore.

Category:	Adverse events, interactions and toxicity of antiinfectives

02:30 - 04:30 PM	Room assignment will be printed in the final program

293	DRUG INDUCED APLASTIC ANEMIA, REVIEW.
Micha Levy
Hebrew University Jerusalem, Israel.

065	Dose-Effects of Fluoroquinolones (FQs) on Intestinal Penetration, Hepatic Isoforms and DNA Damage in Rat.
BERTAZZONI MINELLI E, BENINI A, DORIA D, FRANCESCHETTI P, and 
FRACASSO M E
Dpt. Medicine and Public Health, Pharmacology Section, University of Verona, Verona, Italy.

001	Cefepime-induced Neurotoxicity: A Retrospective Review With a Proposed Mechanism.
ABANADES S1, NOLLA J2, RODRÍGUEZ-CAMPELLO A3, ROSET PN1, FARRE M1
1Institut Municipal d’Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, Spain
2Hospital Universitari del Mar, Universitat Pompeu Fabra, Barcelona, Spain
3Hospital Universitari del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.

246	Impaired Cognition as a Sensitive Index of Antibiotics’  Behavioral Toxicity: A Review.
Khalifa AE
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

049	Interactions of Antiinfectives: A Review.
BARCIA E, NEGRO S
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Spain.

217 	An Overview of Life-Threatening Interaction of Macrolides with Cardiovascular Drugs.
JAMALI F AND DAKHEL Y
Faculty of Pharmacy & pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.

423	Interactions of Antiinfectives.
PONTALI E
Health services – Prison of Genoa; Genoa, Italy.

619	Enzyme Kinetics for Cytochrome P450 (CYP) Inhibition in Antiretroviral Therapy.
ZHI-YI ZHANG, NANCY Y WONG
Drug Safety and Disposition, Eisai Research Institute, Andover, MA, USA.

Category:	Antineoplastic agents - new and known non-synthetic compounds & Antineoplastic agents - clinical studies

02:45 - 05:00 PM	Room assignment will be printed in the final program

340	Alpha-fetoprotein Growth Inhibitory Peptide as an Antineoplastic Therapeutic Agent: The Use of Peptides as Targeted Magic Bullets in In Vitro and In Vivo Models.
MUEHLEMANN M, MIZEJEWSKI GJ
Serometrix LLC, Syracuse, NY, USA.

489	MTC 170 – A novel endogenous magic bullet against cancer.
Schwamberger G1, Freudenberg M², Galanos C2
1 Dept. of Molecular Biology, University of Salzburg, Austria
2 Max-Planck-Institute for Immunobiology, Freiburg, Germany.

133	Overview of Violacein Biological Activities: Biochemical Aspects of Its Cytotoxicity and Strategies to Improve Its Effectiveness.
DURÁN N1,2, JUSTO GZ3, BROMBERG N1, MELO PS3, HAUN M3, FERREIRA CV3, DE MELLO MP4, BINCOLETTO C2, DE SOUZA AO5, DE AZEVEDO MMM1, DE AZEVEDO MBM1, LEON LL6, DE CASTRO SL6
1Instituto de Química, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil; 2Universidade de Mogi das Cruzes, Mogi das Cruzes, SP, Brazil; 3Instituto de Biologia, UNICAMP; 4CBMEG, UNICAMP; 5USP-RP, Ribeirão Preto, SP, Brazil; 6FIOCRUZ, Rio de Janeiro, RJ, Brazil.

332	Effects of indole phytoalexins on growth of cancer cells.
MEZENCEV R1, PILATOVA M1, MOJZIS J1, KUTSCHY P2 
1Medical Faculty PJ Safarik University, Kosice, Slovakia; 2Faculty of Science PJ Safarik University, Kosice, Slovakia.

470	Promotion of targeted anticancer apoptosis: a natural “magic bullet”.
SALGANIK RI, ALBRIGHT CD, VAN DYKE TA
The University of North Carolina, Chapel Hill, NC, USA.

610	Anticarcinogenic Effects of Panax ginseng C.A. Meyer and Identification of Active Compounds, Including Enzymatically Producible Ginsenosides Rh2, Rg3 and Rg5 from Red Ginseng.
YUN T-K
Korea Institute for Cancer Chemoprevention, Seoul, Korea.

541	Stromal targeted therapy: will manipulation of the haemopoietic microenvironment improve outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML)?
S Tauro
University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, UK.

513	Phase I/II study of adenovirus-interferon-g (TG1042) in primary cutaneous lymphomas (CL).
Slos P*, Urosevic M, Bleuzen P*, Bataille V*, Burg G, Squiban P*, Dummer R
University Hospital Zurich, Switzerland. *Transgene, Strasbourg, France.

570	The independent prognostic effect of co-morbidity in lymphoma patients: results from the population-based Eindhoven Cancer Registry.
D.J. VAN SPRONSEN 1 (1), M.L.G. JANSSEN-HEIJNEN2, V.E.P.P. LEMMENS2, W.G. PETERS3, J.W.W. Coebergh2
1Department of Medical Oncology, UMC St Radboud, Nijmegen, The Netherlands
2Comprehensive Cancer Centre South, Eindhoven, The Netherlands 
3Department of Internal Medicine, Catharina Hospital Eindhoven, The Netherlands.

Category:	Clinical studies and use of antibiotics

02:45 - 05:15 PM	Room assignment will be printed in the final program

102	Azythromycin versus doxycycline treatment in early Lyme borreliosis: Clinical outcome and antibody response.
CHRISTOVA I
National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.

345	Cerebral Blood Flow, Metabolism and Flux in Patients with Acute Bacterial Meningitis (REVIEW).
MØLLER K
Department of Infectious Diseases, University Hospital Rigshospitalet, Copenhagen, Denmark.

515	The Importance of Combating Plaque Biofilm for Oral and Systemic Health.
SOORY M
GKT Dental Institute, King’s College London, UK.

549	Moxifloxacin as an Alternative Antimicrobial Prophylaxis of Bacteraemia Following Dental Procedures.
TOMÁS I1, LIMERES J1, ALVAREZ M2, LÓPEZ-MELÉNDEZ C2, MEDINA J3, DIZ P1.
1-Santiago de C. University, Spain; 2-Xeral-Cíes Hospital, Vigo, Spain; 3-CHUS, Santiago de C., Spain.

522	An Overview of Skin Infections and Application of Non-invasive Methods for the Evaluation of the Skin Condition.
STAMATAS GN, KOLLIAS N
Johnson & Johnson, Skillman, New Jersey, USA.

524	The Potential Risk of Erythromycin as Emperic Therapy for Therapy Failure in Acute Respiratory Tract Infections.
	NYS S1, TJHIE JHT2, SPEE K1, BARTELDS AIM3, HEIJNEN MLA4, PEETERS MF5, STOBBERINGH EE1
1University Hospital Maastricht, Maastricht; 2PAMM Laboratory, Veldhoven; 3Nederlands Instituut voor Onderzoek in de Gezondheid (NIVEL), Utrecht; 4Centrum voor infectieziekten en Epidemiologie (RIVM), Bilthoven; and 5Streeklaboratorium voor Volksgezondheid, Tilburg, The Netherlands.

419	Treatment of Streptococcus pneumoniae Bacteremia (SpB). Are Two Drugs Better than One?
Plouffe JF1, Martin D1
1University Hospital, Columbus, OH, USA.

204	Penicillin Remains the First Drug of Choice for the Treatment of Pneumococcal Pneumonia in Taiwan with High Rate of Penicillin Resistance in Streptococcus pneumoniae.
Hsueh PR,1 Huang WK,2 Teng LJ,1 Shyr JM,3 Liu YC2
1National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei; 2Kaoshiung Veterans General Hospital, Kaoshiung; 3Taichung Veterans General Hospital, Taichung, Taiwan.

017	Determining the clinical utility of the urine pneumococcal antigen in the diagnosis and empiric management of community acquired pneumonia.
Zakari Y. Aliyu, DA Colvin, HM Salihu, DK Walshe, S Ondiek
St. Agnes Hospital, Baltimore Maryland.

135	Thyroid Tuberculosis: Diagnosis and Treatment about 8 cases.
EL MALKI H O1, BENJELLOUN H2, AMAHZOUNE M1, MOHSINE R1, CHEFCHAOUNI M C1, OULBACHA S1, IFRINE L1, BELKOUCHI A1, BALAFREJ S1.
1Clinique chirurgicale “A” Hôpital Ibn Sina, faculté de médecine et de pharmacie Rabat-Morocco
2Cardiologie “A” Hôpital Ibn Sina, faculté de médecine et de pharmacie Rabat-Morocco.

Category:	Clinical studies and use of antibiotics

03:15 - 04:45 PM	Room assignment will be printed in the final program

633	The Future of Premature Infants During Paul Ehrlich’s Time.
GOLOMBEK SG1
1The Regional Neonatal Center, Westchester Medical Center/New York Medical College, Valhalla, New York, USA.

586	Another Kind of Magic Bullet.
WARWICK WJ
Minnesota Cystic Fibrosis Center, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

240	Pediatric Febrile Neutropenia: 14 Years Experience.
R KEBUDİ1, İ AYAN1, Ö GÖRGÜN1, N GÜRLER2
İstanbul University, 1Oncology Institute, Division of Pediatric Oncology,2Department of Microbiology, İstanbul, Turkey.

157	Is Prophylactic Administration of Antimicrobial Agents to Surgical Patients a Safe Procedure? The anesthesiologist’s point of view.
FODALE V, PRATICO’ C, LUCANTO T, SANTAMARIA LB.
University Hospital, Messina, Italy.

279	Atypical Features of Leptospirosis – A Study at Pondicherry, India.
DUTTA TK, CHRISTOPHER MA, AHMED SM, KANUNGO R, DAS AK
Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry, India.

013	Failure of a Short-Term Antibiotic Therapy for Human Brucellosis – What is Currently the State of the Art?
Al Dahouk S1, Nöckler K2, Tomaso H1, Hagen RM1, Wittig M1, Scholz HC1, Neubauer H1
1Bundeswehr Institute of Microbiology, Munich, Germany; 2Federal Institute for Risk Assessment, Berlin, Germany.

Saturday, September 11, 2004

Category:	Microbiology & Resistance to antiinfectives

07:30 - 09:30 AM	Room assignment will be printed in the final program

270	Anaerobes and Production of β-Lactamases in the Upper Respiratory Tract in Early Childhood.
KÖNÖNEN E
National Public Health Institute (KTL), Helsinki, Finland.

605	Antibacterial Activities of Antibiotic Bonded/Impregnated Catheters.
YORGANCI K1, KREPEL C2, WEIGELT JA3, EDMISTON CE2
1Hacettepe University, Faculty of Medicine, Dept. of Surgery, Ankara, Turkey, Medical College of Wisconsin, 2Surgical Research Lab. and 3Dept. of Surgery, Milwaukee, Wisconsin, USA.

041	Antibiotics inhibiting the ribosome: structure and function.
1AUERBACH T, 1BARAM D, 1ZARIVACH R, 1SITTNER A, 1BASHAN A, 1,2PYETAN E, 2SCHLUENZEN 2F, HARMS, 2J, BERISIO R AND 1,2YONATH A
1Weizmann Institute of Science, Rehovot, Israel, 2Max-Planck Research Unit for Ribosomal Structure, Hamburg.

418	Phenotypic Resistance: The Next Battleground in Treatment Effectiveness.
PLOTKIN BJ1, KONAKLIEVA MI2
Midwestern University, Downers Grove Illinois, U.S.A.; American University, Washington, D.C., U.S.A.

070	Application of the Resistance Prevention Concentration (RPC) & Minimal Inhibitory Concentration (MIC) of Clinical Isolates of Streptococcus pneumoniae (SP) Against Macrolides.
BLONDEAU JM1,2, BORSOS S1
1Royal University Hospital, Saskatoon, SK, Canada, 2University of Saskatchewan, Saskatoon, Canada.

206 	Physiological costs of antibiotic resistance.
Hughes D, Macvanin M, Komp Lindgren P, Marcusson LL, Norström T
Department of Cell and Molecular Biology, Microbiology Programme, Box 596 BMC, Uppsala University, Uppsala, Sweden.

266	Efflux Mediated Antibiotic Resistance in Clinical Isolates of Pseudomonas aeruginosa.
T. Köhler
Dept. of Microbiology and Molecular Medicine, University of Geneva, Switzerland.

306	Antibacterial Photodynamic Inactivation of Multi-resistant Staphylococci Strains.
MAISCH T1, BOSL C1, SZEIMIES R-M1, LOVE B2, ABELS C1
1University Hospital of Regensburg, Germany, 2 Destiny Pharma, Brighton, UK.

Category:	Antiviral agents

07:30 - 10:00 AM	Room assignment will be printed in the final program

414	Interferon; between magic bullet and panacea.
Toine Pieters
VU-Amsterdam Medical Centre, Department Metamedica, Amsterdam, The Netherlands.

466	Expression of Suppressor of Cytokine Signaling 3 (SOCS3 ) in Bone Marrow Cells from Chronic Myelogenous Leukemia (CML) Patients associated with Cytogenetic Response to Interferon-alpha (IFN-a).
SAKAI I1, TAKEUCHI K1, NARUMI H1, YASUKAWA M1, FUJITA S1
1Ehime University School of Medicine, Sigenobu, Japan.

033	Elucidation of a Novel Molecular Mechanism by which Influenza Develops Resistance Against Amantadine, the M2 Channel Blocker.
Astrahan P1, Kass I1, COOPER MA2, ARKIN IT1
1Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel; 2Akubio Limited Cambridge, UK.

377	Antagonistic Combined Effects of Ribavirin and Some Picornavirus Replication Inhibitors.
Nikolaeva-Glomb, L and Galabov, A S
The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences.

540	Meclofenoxate (Centrophenoxine, Acephen, etc.) can inhibit the retrovirus budding on the plasma membrane of lymphoid line cells.
Tatariunas A.
Kaunas Medical University, Lithuania.

560	Antiretroviral compounds interfere with cytotoxic T lymphocytes functions.
TRABATTONI D1, PICONI S1, BIASIN M1, SCHENAL M1, RUSCONI S4, CLERICI M1
1Chair of Immunology, DISP LITA VIALBA, and 2Infectious Diseases Clinic, University of Milano, Italy.

573	Biologic Properties of Structurally Modified b-Lactams Acting as Protease Inhibitors.
VEINBERG G, VORONA M, SHESTAKOVA I, KANEPE I, LUKEVICS E
Latvian Institute of Organic Synthesis, Riga, Latvia.

107	The stable cyclotide framework for the delivery of therapeutic peptides: anti-HIV activity of kalata B1.
CRAIK DJ1, COLGRAVE ML1, DALY NL1, GUSTAFSON KR2
1Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. 2Molecular Targets Development Program, National Cancer Institute, Frederick, USA.

421	Comparative Molecular Surface Analysis (CoMSA): Application for Diketoacid (DKA) Pharmacophore Mapping in HIV Integrase Inhibitors.
J. Polanski1, H. Niedbala1, R. Musiol1, B. Podeszwa1, D. Tabak1, A. Palka, J.-F. Mouscadet2, R. Gieleciak1, A. Bak1, T. Magdziarz, J. Gasteiger3, M. Le Bret2
1Department of Organic Chemistry, University of Silesia, Katowice, Poland,  2CNRS UMR 8532, LBPA, Ecole Normale Supérieure de Cachan, Cachan, France, 3Computer-Chemie-Centrum, Institute of Organic Chemistry, University of Erlangen-Nürnberg, Erlangen, Germany.

565	A primary macrophage model – a simple approach to study the effect of antiviral agents as well as host susceptibility to flavivirus West Nile.
PANTELIC L, UROSEVIC N
Microbiology, School of Biomedical and Chemical Sciences, The University of Western Australia, Nedlands/Perth, Australia.

Category:	Mechanisms of pharmacological importance

08:00 - 09:45 AM	Room assignment will be printed in the final program

239	Biochemical Characterization of the Doxorubicin Transporter from Streptomyces peucetius.
KAUR P and GANDLUR SM
Department of Biology, Georgia State University, Atlanta, Georgia, USA.

221 	The Antinociceptive response of Buthus martensi Karsch (BmK) AS, a Na channel Receptor Site 4 Modulator, and its possible underlying mechanism.
JIN Chen1, Xing-Hua Feng1, Jian Shi1, Zhi-Yong Tan2, Yong-Hua Ji1CA
1The Key Laboratory of Neurobiology, Institute of Physiology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai P.R. China; 2Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut, USA.

275	Fluorescence Correlation Spectroscopy: a new tool for characterizing DNA plasmid condensation.
KRAL T1,2, LANGNER M3,4, HOF M1
1J. Heyrovský Institute, CAS and Center for Complex Molecular Systems and Biomolecules, Prague, Czech Republic, 2Agricultural University, Wrocław, Poland, 3Wrocław University of Technology, Wrocław, Poland, 5Academic Centre for Biotechnology of Lipids Aggregates, Wrocław, Poland.

302	Fibroblastic Cells from Human Periapical Granulation Tissue (HFC) Preferentially Form Calcified Matrices in Rat Decalcified and Boiled Bone (DBB).
MAEDA H1, WADA N1, FUJII S1, NODA R1, AKAMINE A 1
1Kyushu University, Fukuoka, Japan.

325	The c-kit mutation D816V induces differentiation and cluster formation in Ba/F3 cells and predicts the pathology and clinical course of indolent systemic mastocytosis.
Matthias Mayerhofer, Peter Valent
University of Vienna, Austria.

357	Relevance Of Surface Activity And Liquid Membrane Phenomena In Tissue Penetration And Drug Absorption.
Nagappa AN1
Pharmacy Group, Birla Institute of Technology and Science, Pilani, India.

373	Hypericin Derivative as a Magic Bullet for in vivo Targeting Hepatic and Cardiac Infarction.
NI Y1, BORMANS G2, CHEN F1, FONGE H2, VERBRUGGEN A2, MARCHAL G1.
Departments of Radiology1 and Radiopharmaceutics2, University Hospital Gasthuisberg, K.U. Leuven, Belgium.

Category:	Clinical studies and use of antibiotics

08:15 - 09:30 AM	Room assignment will be printed in the final program

346	Prophylaxis of the Systemic Inflammatory Response Syndrome (SIRS) with N-acetylcysteine treatment: a Magic Bullet or a Fraud?
MOLNAR Z
University of Pécs, Pécs, Hungary.

589	A holistic approach to MRSA-eradication using intravenous linezolid/rifampicin, intratracheal vancomycin, nasal mupirocin, cutaneous and enoral chlorhexidin plus povidone-iodine in critical ill patients with MRSA-pneumonia.
Wenisch C1, Krause R1
1Infectious Diseases and Intensive Care, Medical University Graz, Austria.

315	The influence of local infusion of fusidic acid in the development of septic complications after lung resections.
MARKOGIANNAKIS A1, SFYRIDIS P2, BALTAYIANNIS N2, TSAKRIS A1, 
HATZIMICHALIS A2
1Faculty of Nursing, University of Athens, Greece; 2Metaxa Cancer Hospital, Piraeus, Greece.

072	Infectious Complications in Hematopoietic Stem Cell Transplant  Recipients: Experience at Pisa General Hospital.
M. Bonadio, G. Morelli, S. Mori, R. Riccioni, E. Tagliaferri, M. Petrini
Section of Infectious Diseases and Hematology Unit, University - Hospital, Pisa, Italy.

173	Six Years Experience of Using Meropenem & Vancomycin in First-line Empiric Antimicrobial Regimens in Paediatric Haematology & Oncology (PHO).
GRAY JW
Birmingham Children’s Hospital (BCH), UK.

Category:	About mechanisms and Magic Bullets

09:45 - 12:00 PM	Room assignment will be printed in the final program

486	Magic Bullets and Lectins Reunited – Ehrlich´s Contribution to Lectinology.
Schumacher U1, Mewe M1, Thies A1, Schneppenheim R2, Pfüller U3 Tielker D4, Jäger KE4
1Experimental Morphology, Hamburg, 2Pediatric Oncology, Hamburg, 3Phytochemistry, Witten-Herdecke, 4Forschungszentrum Jülich.

004	Treatment of Glucosphingolipid Storage Disorders with Novel Inhibitors of Glucosylceramide Synthase.
ABE A1, WILD S1, LEE L1, SHAYMAN JA1
1University of Michigan, Ann Arbor, MI, USA.

022	How Does Rhodococcus opacus Adapt to Environmental Stresses?
ALVAREZ HM, SILVA RA, ALVAREZ AF, BARRÍA M
Departamento de Bioquímica, Facultad de Ciencias Naturales, Universidad Nacional de la Patagonia San Juan Bosco, Comodoro Rivadavia, Chubut, Argentina.

435	Ehrlich’s “magic bullet” and current situation with infectious diseases.
SMITHYMAN AM1, RAJASEKARIAH GR1
1Cellabs Pty Ltd, Dale St, Brookvale, NSW, Australia.

046	FROM  “BLUTGIFT”  TO  BIO - WEAPON:  RICIN - 2004.
BALINT GA
Laboratory of Clinical Pharmacology, Dept. of Psychiatry; New Clinics; University of Szeged Medical School, SZEGED, HUNGARY.

310	SINGLE AGENT ONE DOSE THERAPY VERSUS MULTIPLE AGENT POLYTHERAPY FOR PROPHYLAXIS IN MINILAPAROTOMY HYSTERECTOMY: OUR EXPERIENCE.
MONIKA MALHOTRA ,JB SHARMA, R.ARORA, S BATRA
Department of Obstetrics and Gynaecology, Maulana Azad Medical College, New Delhi, India.

455	Perilymph time-concentration profile of guinea pig cochlea after systemic and local application of caroverine.
CHEN  Zhiqiang a, b,DUAN  Maoli b, RUAN Runsheng a,c,ULFENDAHL Matsb
aDepartment of Otolaryngology, National University of Singapore, Lower Kent Ridge Road, Singapore
bDepartment of Clinical Neuroscience and Center for Hearing and Communication Research, Karolinska Institutet, Stockholm, Sweden
cInstitute of Bioengeneering and Nanotechnology, The Nanos, Singapore.

631	The Era of Targeted Therapies in Cancer.
Miguel H. Bronchud
Clinical Oncology, Hospital General of Granollers Barcelona- Spain.

646	Chaos, Cancer and The Cellular Operating System.
JONES AS, TAKTAK A, FISHER A and HELLIWELL T
The University of Liverpool, Faculty of Medicine.

Category:	Blood brain barrier

10:00 - 11:00 AM	Room assignment will be printed in the final program

008	Applications of a Blood-Brain Barrier Technology Platform to predict CNS penetration of drugs in various series of therapeutics families. I. Computational Model.
ADENOT M1, PERRIERE N1,2, SCHERMANN JM2, LAHANA R1
1Synt:em, Nîmes, France;  2 INSERM U26, Hôpital F.Widal, France 

283	Neuroinflammation results in openning blood-brain barrier/BBB/ for peripheral peptides.
KWIATKOWSKA-PATZER B, KLINOWIECKA A. KOSSON P, WALSKI M, FRONTCZAK-BANIEWICZ M, LIPKOWSKI AW
Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.

420	Pathological Opening of the Blood-Brain Barrier (BBB) to Horseradish Peroxidase (HP) and Amyloid Precursor Protein (APP) Following Ischemia-Reperfusion Brain Injury.
PLUTA R1,2
1Medical Research Centre, Warsaw; 2Pedagogical University, Częstochowa, Poland.

076	MANIPULATING THE BLOOD BRAIN BARRIER FOR STEM CELL THERAPY IN STROKE
Cesar V Borlongan1,2,3*, Cyndy D Davis4, Paul R Sanberg4, 1Dept Neurology, 2Inst Molecular Medicine and Genetics, Medical College of Georgia; 3Augusta VAMC, Augusta GA 30912; 4Center of Excellence for Aging and Brain Repair, University of South Florida College of Medicine, Tampa FL.

Category:	Mechanisms of action of antineoplastic agents including resistance

10:10 - 11:40 AM	Room assignment will be printed in the final program

297	An ATP-Dependent Switch Controls the Transport Cycle of the Multidrug Resistance P-Glycoprotein.
LINTON KJ1, ZOLNERCIKS JK1, WOODING C1, KERR ID2 and HIGGINS CF1.
1MRC Clinical Sciences Centre, London, UK. 2University of Nottingham, Nottingham, UK.

099	Development Of a Novel Resistance Modifying Agent To Overcome Multidrug Resistance In Cancer.
	S K CHOUDHURI, P DUTTA, S MAJUMDER and A MOOKHERJEE
Department of Environmental Carcinogenesis and Toxicology Chittaranjan National Cancer Institute, Calcutta, INDIA.

193	Multidrug Resistance Gene (MDR1) Polymorphism G1199A alters P-Glycoprotein Efflux Activity and Drug Resistance (new data).
	WOODAHL EL, YANG Z, BUI T, SHEN DD, HO RJY
University of Washington, Seattle, WA, USA.

463	Possible Molecular and Cellular Action Mechanisms of Catechins Explaining the Beneficial Effects of catechins on the Development of Cancer Diseases.
	AGAPIOS SACHINIDIS
Center of Physiology and Pathophysiology, Institute of Neurophysiology, Cologne, Germany.

625	Molecular mechanisms for the repair of DNA damage induced by anticancer topoisomerase inhibitors.
	ADACHI N, IIIZUMI S, SO S, KOYAMA H
Kihara Institute for Biological Research, Yokohama City University, Yokohama, Japan.

608	Magic bullet for breast cancer prevention: To prevent the formation of  estrogen epoxide.
Yu FL
Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, USA.

Category:	Agents involving the immune system

11:15 AM - 01:00 PM	Room assignment will be printed in the final program

299	From the Magic Bullet to a Better Fort - Up Regulation of Host Immunity.
LORIA RM.
Virginia Commonwealth University, Medical Center, Dep of Microbiology,  Immunology, Pathology and Emergency Medicine,  Richmond Va. USA.

300	Magic Bullets for Cancer Drugs and Cancer Gene Therapy.
LUNDSTROM K
Regulon Inc.,/Cancer Therapeutic Sciences, Epalinges (Lausanne) Switzerland.

403	Magic bullets – magic ghosts: targeting of colon cancer cells and macrophages by bacterial ghosts loaded with doxorubicin.
Paukner S.1, 2, Kohl G.2 and Lubitz W.1, 2
1Institute for Microbiology and Genetics, Vienna Biocenter, University of Vienna, Austria 
2BIRD-C GmbH & Co KEG, Vienna, Austria

433	Ehrlich ascites tumor as a tool in the development of compounds with immunomodulatory properties.
QUEIROZ  MLS1, VALADARES MC1, BINCOLETTO C1,2
1Departamento de Farmacologia/Hemocentro, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil; 2Centro Interdisciplinar de Investigações Bioquímicas, Universidade de Mogi das Cruzes, Mogi das Cruzes, SP, Brazil.

578	Immunologically Specific Activation of Anticancer Prodrugs by Monoclonal Antibody -Lactamase Conjugates.
VRUDHULA VM,  KERR DE,  SIEMERS NO,  SVENSSON HP,  WALLACE PM, SENTER PD
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, U.S.A.

603	Identification of a small molecule organic compound for prevention of complement-mediated immune hemolysis.
YAZDANBAKHSH K1, MQADMI M1, ZHENG X1, SONG J1, ABRAMOWITZ S1, GICLAS,P2
1Complement Biology, New York Blood Center, New York, USA.
2Complement Laboratory, Pediatrics Dept, National Jewish Medical and Research Center, Denver, USA.

623	Knockdown of PU.1 by siRNA on CD34+ Hematopoietic Stem Cells Derived from Mouse Embryonic Stem Cells Turns Cell Fate Determination to pro-B Cells.
ZOU GM1,2,, CHEN JJ1, WU W1, ROWLEY JD1
1Section of Hematology/Oncology. Department of Medicine. University of Chicago Medical Center; USA. 2Current address: Herman B Well Center for Pediatrics Research. Indiana University School of Medicine.

Category:	Design of drug delivery & Vaccination 

12:15 - 01:15 PM	Room assignment will be printed in the final program

118	Delivering the Magic Bullet: The Role of Transporters in Rational Drug Design.
WALLACE LMJ, AJITH SN, AL-SALABI MI, BURCHMORE RJS, CANDLISH D, GOULD MK, JABEEN I, DE KONING, H.P.
University of Glasgow, Glasgow, UK.

318	Receptor-Mediated Endocytosis: A Pathway for Drug Delivery and a Target for Drug Design.
V MARSHANSKY
Program in Membrane Biology, MGH, Department of Medicine, Harvard Medical School, Boston, MA, USA.

308	Interest of Fluorine-19 Nuclear Magnetic Resonance (19F NMR) to Detect, Identify and Quantify New Metabolites of Fluorinated Antifungal and Anticancer Drugs in Humans.
MALET-MARTINO M, MARTINO R, GILARD V, DESMOULIN F
Biomedical NMR Group, SPCMIB Laboratory, Paul Sabatier University, Toulouse, France.

126	Oral Vaccination Against Typhoid Fever.
Guido Dietrich
Berna Biotech Ltd, Berne, Switzerland.